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Congenital heart defects in the pediatric population require severe surgery to 
reconstruct vessels and structures in malformed heart tissue. Reconstructive surgery 
at an early age leaves many patients with synthetic, non-living and possibly failing 
grafts that require subsequent surgeries. A biodegradable scaffold can support 
regeneration of the vascular wall by the patient’s own tissues, and eventually degrade 
away, leaving a functional and patient maintained tissue in its place. Extracellular 
matrix (ECM) based scaffolds are uniquely equipped to enhance host cell recruitment 
and modulate the immune response. Natural healing responses are initiated by native 
biochemical and physical cues provided by the ECM to endothelial cells and key 
immune system responders. However, ECM-based scaffolds may degrade rapidly or 
not possess the elastic strength required for vascular grafts. The work presented here 
is aimed at the development of a biohybrid scaffold, consisting of the ECM-based 
material pericardium and synthetic polymers. This combination results in a single 
  
material that retains mechanical integrity from the polymer and provides bioactivity 
from the pericardium matrix. The first aim of this research develops a compliant 
patch material as a replacement for chemically crosslinked pericardium currently used 
in surgical applications. Reinforcing pericardium with the polymer PPF creates a 
mechanically resilient scaffold, with reduced inflammatory markers compared to 
chemically crosslinked or untreated controls. In addition to cues provided by the 
matrix molecules of pericardium, the polymer layer can serve as a platform to further 
facilitate or direct the remodeling by releasing bioactive cargo from the polymer layer 
to the pericardium matrix. The benefits of the hybrid material are not limited to a 
layered scaffold, as demonstrated in the second aim. Here, the applicability of the 
pericardium polymer hybrid is expanded to control shape and mechanical properties 
in a hydrogel scaffold. In this dissertation, we have successfully developed two 
distinct hybrid materials that maintain the bioactivity of an ECM-based material to 
support native cell remodeling, and incorporate control over degradation and 
magnitude of host response from the polymer. Used as vascular scaffolds, these 
materials have potential to reduce subsequent surgical intervention by creating a 
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Chapter 1: Introduction to Tissue Engineered Vascular 
Scaffolds 
Surgical reconstruction of blood vessels and cardiac tissue is frequently required to 
repair or restore anatomic configuration following cardiovascular defects, disease 
or injury. Congenital cardiovascular disease, also known as congenital heart 
defects (CHD), describe cases in the pediatric population where structural 
problems arise from abnormal formation of the heart or major blood vessels. Of all 
population groups, pediatric patients have the longest potential demand for the 
replacement, thus it is especially essential that repairs are both appropriate and 
long lasting.   
CHD is one of the most prevalent birth defects, affecting 1% of live births in the 
U.S. (1). A number of anomalies associated with this disease will require severe 
surgical vessel reconstruction, often with help from a prosthetic material (2). 
Tetralogy of Fallot, pulmonary atresia with ventricular septal defect, and Loeys-
Dietz syndrome (LDS) are just a few examples of disorders requiring different and 
custom surgical intervention and reconstruction of major arteries (3). In these 
diseases, major vessels are formed with extreme tortuosity, enlargement, 
occlusion, or mismatched origins. In addition to inefficient blood transport, there 
is high risk and occurrence of vascular aneurysm and dissection (4). Surgical 
repair approaches may combine cutting away obstructive tissue, adding occlusion 




Improvements in surgical technique and materials have significantly decreased 
mortality in the affected population in recent years, allowing many CHD patients 
to survive into adulthood (6, 7). A growing life expectancy further emphasizes the 
need for a versatile material that can grow and be maintained by the patient as part 
of the native body. Without a “grow-able” device, this population risks multiple 
re-intervention surgeries throughout their lifetime.  
Successful vascular tissue replacements first and foremost must retain elasticity and 
strength over time, without risk of calcifications or other impediments to blood flow. 
A long lasting replacement intended to grow with the patient has the added criteria to 
develop appropriate cell organization at the injured site, and support the somatic 
growth of the patient’s tissue that can replace the scaffold as it degrades over time.  
Current material options for use in cardiac surgeries include autologous or 
xenographic tissues, synthetic materials, and, more recently, tissue engineering based 
strategies. Autologous or xenographic tissues have been most widely utilized over the 
past 60 years (8). Historically, a common, xenographic material used for CHD as well 
as many other vascular prosthetic uses is glutaraldehyde (GA) crosslinked bovine 
pericardium (9-11). Pericardium is the fibrous membrane enclosing the heart muscle. 
Due to the unique composition of primarily collagen, elastin, and 
glycosaminoglycans, pericardium has a mechanical profile which resembles that of 
vascular tissue. In both tissues, the protein fibers make up a strong and elastic 
biomaterial that is well suited for the high stress environment of the cardiovascular 




implantation, most xenographs are treated with GA, which chemically crosslinks the 
tissue’s collagen molecules. This process is effective at stabilizing the tissue against 
chemical and enzymatic degradation, as well as lessening the display of antigenic 
determinants and inflammatory response (8, 12). However, by chemically 
crosslinking the proteins, the potential for viable cell inhabitation and remodeling is 
diminished (13), resulting in a material that can no longer maintain or repair itself. 
The crosslinked product has been associated with local inflammation and severe 
calcifications which can lead to subsequent matrix deterioration and compromised 
mechanical properties (10, 14, 15). These challenges are especially critical in 
pediatric cases, since this calcification and stenosis can occur within 10 years of 
implantation and would require re-intervention (11, 16, 17). Similar challenges 
related to stenosis and eventual loss of function are shared with most synthetic 
grafting material. Even though other commercially available textile materials are able 
to remain durable over long periods of time, there is still no growth potential and 
therefore limited durability in a pediatric patient.   
Recent investigations and developments in engineered tissues have shown great 
progress in the vascular space. These approaches have the ability to grow, heal, and 
provide long-term durability to the vascular injury site. Methodologies following 
two main approaches have emerged: cell-based designs and acellular, material-
based designs. On one hand, cell-seeded, biodegradable tissue engineered grafts 
provide a controlled cell population and can ensure adequate development of 
endothelial and smooth muscle layers before implantation. Both characteristics are 




biodegradable synthetic polymer scaffolds (18), and self-assembled cell sheets all 
have success in this area and have progressed to preclinical (19) and clinical (20) 
studies. A limitation of this approach is that to be used in humans, autologous cells 
would need to be isolated from the patient and expanded before implantation. This 
is typically costly and labor-intensive.   
Acellular techniques, on the other hand, endeavor to build a more scalable and 
easily applied therapy. In this approach, bioactive materials are used to recruit host-
cells, and then support both invasion and differentiation of endogenous cell 
populations to inhabit and maintain the graft site until complete degradation of the 
graft material. Smart design and selection of material for this approach is critical. 
Evidence shows that parameters such as slow-degradation of the material or 
dissimilar mechanical properties result in limited cell infiltration, poor remodeling, 
and improper restoration of function (18).  
Naturally derived materials, such as extracellular matrix (ECM), have been shown in 
many applications to help define the microenvironment and signal the building of site 
appropriate functional tissue (21-23). ECM molecules represent a diverse set of 
structural and functional proteins as well as a variety of growth factors. Native 
binding sites from these molecules and the formation of chemotactic cryptic peptides 
from parent molecules can positively influence remodeling, recruit stem and 
progenitor cells, and modulate the immune response. These steps can ultimately 




As described, ECM-derived proteins provide unmatched cellular recognition, and 
therefore influence cellular response toward predicted remodeling behaviors. 
However, materials built with only these proteins can degrade rapidly or begin too 
weak to substitute for compliant, matrix-dense tissues, such as vasculature. Therefore, 
to achieve the characteristics required of a vascular scaffold, we propose a biohybrid 
material approach. A biohybrid material is able to incorporate polymer components 
with ECM-derived proteins to produce a substrate with desired mechanical and 
degradation properties that can actively guide tissue remodeling.  
This dissertation work aims to provide an alternative approach to cardiac tissue repair 
through the development and characterization of pericardium based biohybrid 
materials. As previously mentioned, pericardium has the appropriate protein 
composition for matching mechanical strength of a vessel wall, as well as the 
bioactivity to recruit and attach native cells. To supplement durability and add 
support during remodeling, we have combined pericardium with biodegradable 
polymers. The objectives of this work are to successfully couple pericardium with a 
synthetic polymer and show retained strength and bioactivity provided by the scaffold 
to endothelial cells and key immune system responders. Specifically, the aims of this 
work are as follows:  
1) Develop an ECM-based hybrid material for vascular wall repair that provides 
strength during remodeling and promotes functional tissue regrowth. 
a. Examine the hybrid material combining a poly(propylene fumarate) 




degradation compared to chemically crosslinked surgical standards in 
a subdermal implant 
b. Characterize the inflammatory response from macrophages to the PPF 
+ pericardium hybrid and determine how to modulate material to 
promote a healing response 
c. Utilize the developed material as a platform to directionally release 
pro-angiogenic factors to the tissue substrate to direct or further 
promote vascular regrowth and reduced inflammation 
2) Establish a 3D printed hybrid hydrogel that promotes wound healing response 
and endothelial cell growth in vascular tissue.  
a. Develop a composition of hydrogel that is biodegradable and 
biocompatible with the high geometric control of a 3D printed scaffold 
b. Demonstrate that the inclusion of bioactive peptides from the 
pericardium promotes the functional regrowth of endothelial cells 
c. Demonstrate the positive, pro-healing response of macrophages in 
response to the hybrid hydrogel 
 
In this dissertation, we have successfully developed two distinct hybrid materials that 
increase the strength of natural ECM without diminishing the potential to promote 
regrowth at the injured site. Scaffolds that combine unaltered structural proteins from 
the native ECM with sustained support from the polymer component result in more 
moderate inflammation and degradation compared to untreated ECM tissue or 




with living tissue, leaving a functional vessel in its place. The availability of a readily 
available grafting material that supports the re-growth of a pediatric patient’s own 
tissue can eliminate multiple operations and morbidities associated with CHD and 








Chapter 2: ECM-Based Biohybrid Materials for 
Engineering Compliant, Matrix-Dense Tissues1 
 
This review will discuss biohybrid materials, or materials with both a synthetic and 
natural component, being developed to rebuild compliant, matrix-dense tissues. These 
materials have great potential for tissue engineering strategies since they combine the 
advantage of a natural substrate, to aid in site specific tissue regrowth, as well as a 
synthetic polymer component, to provide strength to withstand the force from 
environment while the material is remodeled. The applications for these materials 
include skin wound healing, vascular repair and grafts, tendon replacement, and 
intestinal wall reconstruction. We describe the materials fitting this description by 
dividing them into four groups based on fabrication techniques, and then report on 
biological and mechanical property progress in subsequent sections. We conclude 
with a summary of the current work evaluating immune response to the biohybrid 
material, and suggest the need for a more in depth investigation into the relationship.  
2.1 Role of ECM in Engineering Tissue 
No longer casted with a merely supportive role, the extracellular matrix (ECM) is 
now considered to play a major part in tissue morphology and function, defining the 
microenvironment through controlling migration, behavior, and phenotype of resident 
cells (27). The dynamic interaction between ECM and local cells is responsible for 
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mechanical, chemical and physical changes in the tissue (24, 28). As such, the ECM 
must be in constant state of deconstruction and specific rebuilding, based on cellular 
secretions, physical and chemical cues.  
 An ideal scaffold for tissue engineering would not only promote but take active part 
in this constructive remodeling and formation of site appropriate tissue. Material 
choice can be very influential in the overall success and incorporation of an 
implantable scaffold into the rebuilding process. Many implantable materials have 
been engineered to prioritize one of two main characteristics: biological relevancy or 
mechanical consistency to the tissue they are intended to replace.  
 
Biologically relevant materials, such as naturally produced ECM structures, have 
been shown to help define the microenvironment and signal the building of site 
appropriate functional tissue. Matrix molecules represent a diverse set of structural 
and functional proteins, glycoproteins, and glycosaminoglycans that are arranged in 
an ultrastructure that is unique to each anatomic location. A variety of growth factors 
and binding sites have been described in nearly every tissue, specific to the 
environment and contained or transported through the ECM, as well. As described, 
the ECM provides a naturally occurring and highly conserved substrate for cell 
viability and growth through biological and chemical cues. Fragments of parent 
molecules, including collagen and fibronectin, have been shown to promote activities 
including angiogenesis, anti-angiogenesis, antimicrobial effects, and chemotactic 
effects.  It is hypothesized that the specialized composition including structural and 




cryptic peptides, can recruit stem and progenitor cells and contribute to modulating 
the immune response. Successful stem and progenitor cell recruitment together with a 
moderate immune response have significant influence when determining the success 
of an implantable scaffold (22, 24, 25, 29). 
 
Due to this highly specified nature, ECM-based materials have great and perhaps 
unparalleled potential to control the biological activities of cellular recognition and 
colonization. In addition to, or in fact because of, the particular composition of 
material, mechanical and physical characteristics of ECM are unique and highly 
specific. In fact, many of the ECM-based implantables that are commercially 
available today are utilized only for mechanical properties, intentionally blocking any 
chemical or biological identifiers (9, 30).  
 
The complexity of ECM makes identifying and understanding the minute components 
challenging, and because the constitution is only partially understood, it becomes a 
difficult material to replicate. ECM protein identification was pursued by Hansen et 
al, who used a novel combination of rapid ultrasonication and surfactant assisted 
digestion to aid in proteonomic analysis of tissue derived ECM (31). Their results 
reveal hundreds of previously unidentified proteins in rat mammary glands that were 
substantially different from those in matrigel alternatives. Human mammary epithelial 
cells cultured in each of the two mediums demonstrate significantly different 
behavior, indicating that inaccuracies of mimicking cellular ECM constitution could 




ECM derived tissue has been implicated in cellular behavior influences as well. In a 
study conducted by Xu et al. to mimic the ECM using a synthetic component,  they 
found that minor changes in fiber diameters (1.28-1.50 µm), fiber density (22.2-46.1 
# of fibers/100µm
2
), and fiber alignment (0.45-0.60 angular distribution), as well as 
resulting changes to the construct modulus, had significant effects on cardiac cell 
differentiation and growth (32). This study agrees with many, that the precise 
composition and physical appearance of cell substrate, natural ECM or synthetic 
scaffold, can drastically direct cell and therefore tissue function (33). 
Considering the unique advantages of ECM-based materials, and the complexity to 
replicating the naturally composed tissue, a hypothetical ideal tissue engineering 
scaffold would utilize ECM already produced, on a site and person specific basis. 
Unfortunately, ECM if left untreated has several challenges to consider before 
including it in an implantable scaffold material.  
 
ECM-based material is observed to degrade rapidly when implanted in a foreign 
body. It has been reported to have degraded significantly in 2-3 weeks in vivo in a 
subdermal implant,(34) 60% in 30 days and 100% at 90 days in an in vivo tendon 
repair model.(35) The incorporation into self-sustained material through constructive 
remodeling can be a long process, and the material needs to retain designed physical 
properties until that time. A synthetic material, on the other hand, is much less 
vulnerable to proteolytic enzymes and degradation tactics, and can be tuned to retain 





As pointed out by Zhu et al, synthetic polymer constituents allow for manipulation of 
a scaffold on a molecular level by controlling polymerization, crosslinking and 
functionalization (36). These are important considerations when engineering soft 
tissue components, as the physical properties of the bulk tissue determine its ability to 
carry out its main function. There has been much development in polymer 
manufacturing techniques to produce materials that can mimic ECM in strength, 
elasticity, and structure of interconnected networks. However, synthetic polymers are 
usually utilized as passive scaffolds, and do not naturally create active cell 
interactions.  
 
By combining blocks of natural tissue ECM with synthetic polymer components, the 
best of both materials can be included in one scaffold. This combination will be 
termed an ECM-based biohybrid material. A biohybrid material for the purpose of 
this review must contain significant blocks of both natural ECM-based material as 
well as synthetic fibers, for the purpose of influencing the biology of the 
microenvironment or providing strength and resistance to degradation. Small-scale 
natural components such as growth factors and small adherent proteins are excluded 
from the natural material category, since they do not play a major role in ECM 
material bulk or mechanical properties.  
2.2 Methods 
In order to prepare a comprehensive review of this topic, a search was conducted 
through Thompson Reuters Web of Science and PubMed to compile recent and 




used to conduct three independent searches of  title, abstract, author key words, and  
key words plus®: “extracellular matrix” near scaffold and poly*, biohybrid and 
polymer and material, and biohybrid and scaffold. Each search yielded 800, 108, and 
85 publications, respectively. Searches were designed to include any material 
containing physiologically built components that was used in combination with a 
polymer as a scaffold. The term biohybrid can be applied in the literature to a material 
that has any part of a biologically created material, including components as small as 
functional molecular groups and growth factors. The search terms were kept 
intentionally broad, and publications that did not involve large ECM-based structural 
proteins were excluded by hand.  From the remaining pool, publications were selected 
for review that matched the above definition of an ECM-based biohybrid material, 
and were used for a compliant, matrix-dense tissue application. Relevant citations 
from or of said papers were reviewed as well. 
2.3 Types of Biohybrid Materials 
Upon review, we see four classes that can describe ECM-based biohybrid materials, 
separated by fabrication and ultimate landscape of the material. Selection of 
fabrication technique is in part dictated by the choice of both polymer and natural 
constituent. The fabrication techniques covered in this review are illustrated in Figure 
2.1.  
 Materials composed primarily of intermingled fibers of both the polymer and 
natural component: The first technique covered in this report is the building of 
a composite by interweaving fibers. Typically, this is achieved by 




methods like co-extrusion can produce this effect as well. Even though 
electrodeposition is capable of producing independent fibers on a micro and 
nano level, the deposition can be random, and cannot account for organized 
bioactive factor incorporation or placement (37, 38).  
 Materials fabricated using the layering technique: The next method covered 
results in a bilayered scaffold, with distinct layers or regions of polymer and 
natural constituents. Regions of each constituent must be large enough to 
locally retain physical properties of the independent constituent. Fabricating 
this way can incorporate whole, decellularized tissue, which allows for the 
inclusion of many (even many unidentified) proteins and minerals.  
 Cell-built ECM layer fabrication method: The third method covered utilizes a 
cell layer to build a matrix on the surface of a polymer scaffold, leaving 
behind a biologically active interface when the cells are removed.  This cell 
laid matrix is the primary biological contribution to the scaffold. This is also 
an effective means to ensure complete inclusion of proteins. For some tissue 
applications, this method is perhaps the closest to reality, if site appropriate 
cells can be cultured. Although, the resources and time to culture could to 
prevent this method from being a scalable procedure.  
 Materials fabricated by blending hydrogel components: The approach is to 
blend together homogenized tissue or ECM components with a soluble 
polymer phase, in order to create one cohesive hydrogel. The blending in this 




level of user control, but eliminates natural structure and organization of the 
tissue components.  
 
Figure 2. 1 Methods of Fabricating ECM-Based Biohybrid Materials. (A) Materials are fabricated 
with interwoven fibers, using either electrospinning, electrospraying, or a combination of the two.  (B) 
Materials are fabricated by blending hydrogel components of ECM derived proteins and polymer 
chains. (C) Materials are built using a layering technique, with either a whole tissue or a polymer 
scaffold as a base. (D) Cell-built ECM layer fabrication, where cells are cultured on a polymer 




Based on the variety of material components, and in cases of significant contribution 
from biological material, it can be difficult to define biohybrid material scaffolds 
within traditional categories for standardized surgical implants. With regard to 
mechanical assessment, appropriate testing and measurement protocols to represent 
the most important characteristics of the material could be unavailable. ASTM 
International describes this problem for new biomaterials of tissue engineering 
scaffolds for growth, support, or delivery of cells and/or biomolecules in standard 
F2027. The standard explains that although there are no specific protocols set for 
novel materials, important properties that should be specified include elastic modulus, 
ultimate tensile strength and compressive modulus, among other physical properties 
such as viscosity, density and contact angles when appropriate.  In standard F2150, 
Standard Guide for Characterization and Testing of Biomaterial Scaffolds Used in 
Tissue-Engineered Medical Products, a list is compiled of standards to consult for 
methodology that would be perhaps appropriate based on material characteristics. 
These recommendations are included in Table 2.1. Most of the protocols are designed 





Table 2.1 Selection of Relevant ASTM Standards for Testing Biomaterials 











D412 Standard Test Methods 
for Vulcanized Rubber 
and Thermoplastic 
Elastomers—Tension 
 Suggests a uniform rate of grip 
separation of 500 ± 50 mm/min 
 Material can be in either a dumbbell 
shape, straight line, or ring shape 
D638 Standard Test Method 
for Tensile Properties of 
Plastics 
 Determination of the tensile 
properties of unreinforced and 
reinforced plastics  
 Material can be in standard 
dumbbell-shaped test specimens  
 Preferred testing method for 
materials between 1 and 14 mm 
thick 
D882 Standard Test Method 
for Tensile Properties of 
Thin Plastic Sheeting 
 Determination of the tensile 
properties of  thin sheeting and films 
(less than 1.0 mm (0.04 in.) in 
thickness) 
 Specimens should be of uniform 
width (between 5.0 and 25.4 mm) 
and be at least 50 mm longer than 
the grip separation used. 
 Specimens must have width-
thickness ratio of at least eight shall 
be used 
D1623 Standard Test Method 
for Tensile and Tensile 
Adhesion Properties of 
Rigid Cellular Plastics 
 Specimens should be rectangular, 
round or square and shall have a 




 When testing materials that are 
suspected to be anisotropic, prepare 
duplicate sets of specimens having 
their long axes parallel and 
perpendicular to the direction of the 
cell orientation 
D1708 Tensile Properties of 
Plastics microtensile 
specimens 
 Specimens can be rectangular, round 
or square and should have a 




D3039 Standard Test Method 
for Tensile Properties of 
Polymer Matrix 
Composite Materials 
 Determination of the in-plane tensile 
properties of polymer matrix 
composite materials reinforced by 
high-modulus fibers. 




remains up to the user to determine 















D695 Standard Test Method 
for Compressive 
Properties of Rigid 
Plastics 
 Specimens should be either a right 
cylinder or prism whose length is 
twice its principal width or diameter 
 Preferred specimen sizes are 12.7 by 
12.7 by 25.4 mm  (prism), or 12.7 
mm in diameter by 25.4 mm 
(cylinder) 
D1621 Standard Test Method 
for Compressive 
Properties of Rigid 
Cellular Plastics 
 Specimens should be either square 
or circular in cross section with a 
minimum of 25.8 cm
2
 and a 
maximum of 232 cm
2
 in area. 
 Minimum height should be 25.4 mm 
(1 in.) and the maximum height shall 
be no greater than the width or 
diameter of the specimen. 
F2977 Standard Test Method 
for Small Punch Testing 
of Polymeric 
Biomaterials Used in 
Surgical Implant 
 Specimens should be miniature disks 
of 0.5 mm in thickness and 6.4 mm 
in diameter 
 Test method has been established for 
characterizing surgical materials 
after ram extrusion or compression 
molding 
 Test parameters provide metrics of 
the yielding, ultimate strength, 
ductility, and toughness under 
multiaxial loading conditions 
 
Following a standard protocol to test these new biohybrid materials would help 
identify the effect of various constituents and fabrication techniques to create material 
physically suited for several compliant tissue applications. To summarize the current 
mechanical data on biohybrid materials, mechanical properties, if reported, are often 
under testing conditions unique to the specific application of the study. For example, 
the elastic modulus of a polypropylene and collagen mesh from a tracheal implant 
was evaluated using compressive testing after 6 months implanted (39). It is possible, 




well if evaluated using tension or in a different sample shape. In a discussion on the 
mechanical properties of a polypropylene mesh with dermal ECM for hernia repair, 
one group suggests that a standard should include an analysis of planar biaxial 
mechanics, instead of merely stretching a sample until failure (40). Protocols that may 
have been originally designed for plastics and metals expose tissue to super-
physiological conditions, which may not record the most relevant behavior. To design 
materials for compliant tissue engineering, a portrayal of stress and strain in a multi-
axis relationship could be the closest to realistic physiological challenges.  
2.3.1 Materials Fabricated with Interwoven Fibers  
Building a scaffold by weaving or spinning together various compositions of fibers 
and polymer chains is a popular technique for creating hybrid scaffolds. 
Electrospinning and electrospraying provide a controlled way to deposit fibers in a 
designed shape. By controlling the speed and charge of material as it is deposited, the 
resulting woven material can resemble the structure of natural ECM, by producing 
single strand diameters between 50 and 500 nm (37). Additionally, scaffolds 
manufactured on an individual fiber basis can have an open and interconnected 
porous architecture, which can help cells easily penetrate to the inner part of the 
scaffold. The single fiber identity can also provide cell attachment points at each fiber 
junction, similar to collagen fibrous strands in vivo structures (41). This ease of 
infiltration, migration and adherence results in homogenous cell distribution and 





By incorporating both synthetic and natural components into interpenetrating 
networks, each region of the scaffold has identical cell attachment and signaling 
opportunities, and at the same time provides equal stiffness or strength at each point 
of the scaffold. There are typically few to no concentrations of either component, 
which could create a polar or nonbioactive side of the scaffold. As a result, scaffolds 
built in this manner often see uniform degradation and infiltration, as well as uniform 
remodeling (43).  
 
2.3.1.1 Material Selection  
The primary determinant in selecting materials for this fabrication technique is the 
potential for electric deposition. Common materials include poly(ɛ-caprolactone) 
(PCL), poly(lactic acid) (PLA), or poly(lactic-co-glycolic acid) (PLGA), which have 
been extensively developed to electrically deposit, and are biocompatible, strong, and 
biodegradable. Using an electro-spun fiber as a base building block, the biological 
components can be incorporated with either casting, electrospraying, or in some cases 
electrospinning along with the synthetic component. Casting methods have been used 
to incorporate water-soluble collagen nanofibers (44) and ECM-based 
polysaccharides and proteins (45) into PCL electrospun meshes. Since casting 
methods can avoid harsh solvents and conditions, they can be adapted to transport 
cellular constituents to the scaffold. In a study by Koch et al., we see the development 
of vascular grafts by casting fibrin gel with resident cells in a mold around a 





To prioritize an organized, fiber-based deposition, ECM components can be 
incorporated into the polymer phase before it is electrospun. In a study by Hong et al, 
porcine small intestine mucosa (SIS) powder was blended with PCL before it was co-
electrospun with silk fibroin. This method of incorporation  improved hydrophilicity 
of the polymer, and effectively incorporated the biological component (46). Other 
successful applications that rely solely on electrospinning include a blend of 
poly(vinyl alcohol), (PVA), with type I collagen into a single fiber constituent (47), 
and a blend solution of PLGA, gelatin and elastin that was electrospun into  vascular 
grafts (48).   
 
In contrast, using electrospraying techniques in combination with electrospinning can 
maintain the single fiber integrity of the polymer phase, but can apply the control of 
deposition more broadly to the collection of water based biological components. In 
one study, a complete tissue ECM is homogenized and then sprayed onto a poly(ester 
urethane) urea (PEUU) mesh scaffold resulting in interconnected fibrous layers 
embedded in a ECM gel
 
(49). Similarly, by developing a dual head, co-
electrospinning device, a human-like collagen/chitosan blend was able to be co-spun 
into a vascular graft with PLA (36), demonstrating the feasibility of using two 
different solutions to construct a scaffold for blood vessel tissue engineering. Finally, 
by combining the above mentioned methods, a hyaluronic acid (HA) hydrogel 
(Heprasil
TM
) was added via a dual electrodeposition system to PCL-collagen blend 
(PCL/Col), mesh. Collagen was blended with PCL prior to deposition, resulting in an 




segregations.  Simultaneous deposition of HA and PCL/Col allowed HA gel to be 
electrosprayed onto the mesh of electrospun PCL/Col, creating a mesh with hydrogel 
pockets interspersed within a matrix of polymer microfibers (50).
 
This double-team of 
electrospraying and electrospinning is conceivably capable of producing the closest 
replica of  the ECM in vasculature and barrier tissues compared  to an independent 
technique, since it combines fibers with softer gel pockets for a heterogeneous but 
consistent material.  
 
2.3.1.2 Mechanical and Physical Properties 
The geometric properties of scaffolds formed using this fabrication method are highly 
similar to the fibrous network of ECM. The thinly sprayed woven fibers can resemble 
specific components of ECM through intentional size-control by altering composition 
and deposition parameters. As shown by Hong et al., among others, increasing the 
concentration of the SIS powder in the PCL/silk fibroin solution resulted in a 
diameter reduction of the fibers due to increased electrical conductivity (46). The 
increased electrical conductivity appeared to improve the size uniformity as well, 
compared to that of pure PCL fibers (46). Results from incorporating human-like 
collagen/chitosan blend to PCL agree; Zhu et al found the electrospun 
collagen/chitosan/PCL had a more biomimetic structure than pure PLA, as the fiber 
diameters approached the size of the extracellular matrix (36).  
The deliberate deposition of fibers in the manufacturing process makes this method 
well suited to form highly defined cylindrical, or other self-supporting shapes. Since 
most methods contain a polymer phase that solidifies after deposition, fibers can 




combined and held together at junction points in a mesh, form materials with noted 
high flexibility and strength. In one case, blended fibers of PVA and collagen type I 
are gathered into a bundle and three bundles were twisted into a braid with the 
diameter of ~4.5 mm, building a flexible rope (47). It is as a result of this strength in a 
variety of formations that we see many free standing scaffolds where structural 
integrity is crucial. This high structural integrity is an indicator of success in 
applications such as vascular grafts, intestinal lining, skin and even tendon or 
ligament grafts (36, 43, 47, 48).   
 
The mechanical strength is usually determined by the contents polymer phase, not the 
components contained in the hydrogel or biological fibers. As such, maximum 
mechanical strength of the composite can be attributed to the choice of polymer 
component and configuration. In some cases, the nature of the polymer phase can be 
altered by incorporation of biological or other components (46).  A table comparing 
mechanical strength of scaffolds fabricated using the woven fibers methods, as well 
as other methods, is shown in Table 2. While it is by no means to draw specific 
comparisons between the scaffolds, as they are all tested in their own specific shapes 
and thicknesses under different parameters, it can provide a vision of the broad range 





Table 2.2 Mechanical Properties of Select ECM-Based Biomaterials 
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1 PLGA : 2 
gelatin : 1 
elastin 
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2.3.1.3 Biological Properties  
While the woven polymer addition to biological components can improve strength of 
the scaffold, the incorporation of biological elements has a positive impact on the 
biocompatibility of the material. Electrospun pure polymer scaffolds alone have been 
plagued by low cell infiltration, cell adhesion, proliferation, and differentiation, due 
to minimal porosity, hydrophobicty acidic degrading sections, among other problems. 
By increasing the presence of a biological component, these problems can be 
mitigated (50, 53, 58, 59). Improved cell adhesion, infiltration and migration are seen 
as a result of incorporating both natural and synthetic components in many of these 
studies.  
 
By incorporating a significant biological component, cell viability and metabolism 
are seen to improve over the pure polymer control in several studies (36, 60). As an 
example, a biohybrid composite of a ratio of 72 PEUU: 28 ECM gel and a control 
mesh of PEUU were implanted into Lewis rats, replacing a full-thickness abdominal 
wall defect. After 4 weeks of implantation, histological staining showed extensive 
cellular infiltration into the biohybrid scaffold. The newly developed tissue was well 
integrated with the native periphery, while minimal cellular ingress into the 
electrospun PEUU scaffold was observed (49). Similarly, by increasing the SIS 
concentration in the PCL/SF/SIS polymer blend, a high level of initial cell attachment 
was achieved. The result of incorporating the ECM-based material SIS was compared 
to plain PCL/SF fibers, which showed a low level of initial cell attachment compared 




Histological evidence from scaffolds extracted from in vivo experiments in trachea , 
arteries (49), abdominal wall (49), and ligaments (47), all show increased number of 
recruited cells over the polymer scaffold alone. The speed and numbers of migrating 
cells can help determine the success of the implant, especially in cases of trachea, 
vessels, and abdominal wall, where a complete lining is essential to success. PCL 
grafts electrospun and then cast with collagen nanofiber gel showed significantly 
higher cell number stained for nuclei and f actin than PCL alone in a tracheal wall 
implant. In contrast to the control PCL group, the PCL- collagen fiber group showed 
complete regeneration of the tracheal wall, with the mucosal epithelium of the trachea 
completely covered (44).   
 
In addition to cell infiltration and cell attachment, many studies cite an improvement 
in ECM production when ECM-based materials are included. Improved cell 
attachment and ECM production usually results in beneficial remodeling of the 
construct. Specifically, a study by Hong et al. discovered in their in vivo assessment 
of an abdominal wall that biohybrid material started to remodel so significantly that 
its mechanical properties mimicked those of the native abdominal wall. Histological 
methods revealed dense homogenous cell layers, extensive collagen formation, no 
calcification, absence of thrombus, and no evidence of aneurysm. These results were 
compared to polytetrafluoroethylene grafts (that have no ECM-based material 
component), which were occluded with thrombus formation (49). The ability of the 
biohybrid graft to create rapid endothelium is an important success indicator in other 




from a blend solution of PLGA, gelatin, and elastin (PGE), were seen to support 
human aortic endothelial cells (HAECs) in forming a confluent, nonthrombogenic, 
and physiologically competent monolayer, as assessed by tissue factor gene 
expression and protein activity assays. The levels of mRNA/protein activity in 
HAECs grown on PGE scaffolds were similar to those on gelatin or collagen IV-
coated 2-D surfaces. However, analysis of a microarray containing 84 ECM-related 
cDNA probes demonstrated that HAECs on PGE scaffolds expressed an ECM-related 
“transcriptome”, where cells were less activated on 2-D gelatin. This study highlights 
the important role of substrate composition, and suggests that that substrate 
composition plays a greater role than surface topography in affecting the endothelial 
ECM-related “transcriptome” (48). Comparatively, in a study on the hybrid mesh 
PCL/collagen and HA hydrogel loaded with two potent angiogenic growth factors 
(VEGF165 and PDGF-BB) the growth factor-loaded hybrid meshes were shown to 
not only support cellular attachment, but also their infiltration and the recapitulation 
of primitive capillary network in the scaffold’s architecture (50).   
 
It is apparent that PCL is a popular choice for electrospun polymers, used in 
biohybrid material scaffolds for muscular (53), nervous (59), dermal (58), and 
vascular tissue repair (50). Certainly through this frequent review, protocols to 
electrospin the polymer have been optimized, and use of the polymer in biomedical 
implantables has been well accepted. It is possible however, that the popularity and 
progress is reinforcing the repeated selection of PCL, as it may appear as a well-




degradation rate through hydrolysis is fairly slow, cited at longer than 24 months 
(61). This timeline is not ideal for most soft tissue engineering applications. 
Degradation, as well as wettability can be improved through the mixing with ECM-
based proteins (gelatin and collagen) (53, 58), but the rate is still slower than other 
hydrophilic, electrospinable polymers, such as PVA and polyurethane (61). It may be 
beneficial to continue to develop electrospinning techniques with these polymers, or 
investigate the use of others with alternate physical properties.  
2.3.2 Materials Fabricated Using the Layering Technique 
In this fabrication technique, two components are considered as distinct entities that 
are combined in a layered fashion to create one composite material. Because the 
components are not integrated on fiber by fiber basis, the outcomes are evaluated as 
two separate materials. In some cases, the materials are defined by a hierarchy of 
influence, one material as the main focus, and the other material as a support of the 
primary constituent. As such, the primary material often has an outstanding intrinsic 
quality that makes it well suited for the application, such as elasticity or strength, but 
requires additional support in the form of biocompatibility or resistance to 
degradation.  Material fabricated in this way is being developed for skin (62), cardiac 
and vascular tissue (10, 63), and abdominal muscle injury (49). 
 
2.3.1.1 Material Selection  
As the biological component, in some cases, it is beneficial to use an already intact 
tissue. Some tissues, like pericardium, dermis, and intestinal submucosa have very 




applications, the synthetic component is layered on top of or around the tissue to add 
strength to the composite and to prevent against degradation. 
 
Pericardium, one unique material, is well suited for use in a layering application. It is 
clinically used in a chemically fixed form, usually with glutaraldehyde, in heart 
valves, vascular and intestinal patches (11). However, it is a tissue primarily 
composed of extracellular matrix proteins, with few resident cells, and unmatched 
mechanical properties which make it an ideal candidate for an ECM-based biohybrid 
material. In chapter 3, we  describe in depth the coupling of a thin layer of 
poly(propylene fumarate) (PPF) and bovine pericardium. We show that the polymer 
layer can provide initial physical protection from proteolytic enzymes and 
degradation, but leaves the original collagen and elastin matrix unaltered (63). 
Porcine pericardium has also been investigated by other groups, using a polyurethane 
oligomer coating layer, which is found to crosslink with the top surface of pericardial 
tissue. This protective layer is predicted to also prevent against degradation, similar to 
chemical fixation agent, but with less alteration of the underlying tissue (64). Other 
coatings have been investigated with bovine pericardium, including titanium (10), 
polyurethane prepolymer (55), and chitosan or silk fibroin film (65). In one study, 3D 
nanofibers of poly(L-lactic acid)-co-poly-(e-caprolactone) (PLACL) were coated on 
the surface of bovine pericardium. This method introduced valuable porosity and cell 
attachment points, as covered earlier. However, the tissue was also treated with 
glutaraldehyde to crosslink the constituents, which would severely mask biological 
components and alter cell interaction with the tissue 
(66)




pericardium that is surface-crosslinked with woven polymer (commercially, 
orthADAPT PR Bioimplant) has FDA clearance for rotator cuff repair 
(67)
, and is 
reported to have performed better than its pure pericardium predecessor in in vivo 
studies.  This tissue source can provide rich amounts of organized ECM around 
0.5mm thick as a substrate for infiltrating and recruited cells to an injury cite 
(63)
. The 
thickness provides a substantial reservoir for hosting cells, but can take time to 
remodel, and requires support through remodeling. Methods that crosslink the tissue 
reduce the space for cell recognition and habitation, as well as alter the time to 
remodel, since crosslinked tissues do not break down. To fully utilize the benefits of 
the tissue, techniques should be pursued to use pericardium in a way that keeps it as 
close to unaltered as possible. 
 
In other applications, the polymer is the base component, and a weaker natural 
component gel is layered on top or through the pre-formed polymer scaffold. PLGA 
scaffolds filled with a layer of fibrin gel (45), or modified with a layer coating of 
artificial extracellular matrices (aECM) consisting of collagen type I, chondroitin 
sulphate, and sulphated hyaluronan 
(68)
, and laminin, fibronectin, vitronectin, collagen 
type IV and poly(lysine) are examples of this type of combination 
(69)
. Other polymer 





Utilizing more of a traditional layer technique, some scaffolds are first formed in a 




poly(caprolactone-co-lactide)/Poloxamer nanofiber membrane was made using 
electrospinning, and then a hydrogel of gelatin (20%) and dextran (10%) was layered 
on the bottom of the fiber mesh to create a bilayer scaffold 
(62)
. In other studies, 
hybrid scaffolds were constructed by forming funnel-like collagen or gelatin sponges 
on one side of a poly-L-lactide (PLLA) woven mesh (28), or layered around a PCL 
electrospun mesh (33). Neutralized dermal ECM digest has also been used in this 
method, forming a layer to coat a polypropylene mesh 
(72)
. This method is particularly 
adaptable to 3D printing techniques, since the two layers can be formed separately 
with reconciling potentially complex printing parameters. For example, materials that 
are not conducive self-supporting structures can be extrusion printed directly on the 
surface of polymer meshes that would be created using stereolithography, extrusion 
under harsher conditions, or a method separate from 3D printing altogether (73). 
 
2.3.2.2 Mechanical and Physical Properties  
Investigations of mechanical properties are often conducted in comparison to the 
individual components of the layered material. Hydrogels such as collagen, gelatin 
and HA are considered weak independently, but show improved mechanical strength 
with the addition of the polymer layer. This relationship highlights the benefit of the 
fabrication method. For example, when collagen or gelatin is gelled within a PLLA 
scaffold with interconnected pore structures, mechanical strength is increased by the 
presence of PLLA, but interconnected regions of the hydrogel remain unaltered if 
examined in isolation (28). Using a similar fabrication technique, PLGA–collagen 
hybrid scaffold formed from collagen microsponges in the openings of a PLGA 




engineered tissues was tested after 6 months of implantation. Incorporating collagen, 
gelatin, and basic fibroblast growth factor resulted in a significantly higher modulus 
than the pure polymer (7.52 ± 1.60 x 10
-2 
and 3.00 ± 1.60 x 10
-2
), although was still 




With similar conclusions, some have investigated PCL porous scaffolds fabricated 
using a salt leaching technique, and injected with HA hydrogel. As expected, the 
storage modulus of the composite is greater than the hydrogel, and reduced when 
compared to the PCL porous scaffold alone. However, the composite does not show 
major changes in Young’s modulus over the 6 week testing period from plain PCL 
scaffolds (74). The results from this study suggest that the hybrid scaffolds provide 
the potential for high stiffness properties in tension and compression, (presumably 
from the PCL component), while exhibiting the viscoelastic response found in 
hydrogels (HA) and native cartilage tissue. For softer tissue applications however, 
regional mechanical characteristics from a horizontal layered technique appear to 
accurately approximate target tissue. If skin, for example, was approximated as a 
bilayer consisting of the epidermis (modulus, 140 to 600 kPa; thickness, 0.05 to 1.5 
mm) and the dermis (modulus, 2 to 80 kPa; thickness, 0.3 to 3 mm), then a bilayer 
scaffold of PLCL/Poloxamer nanofibers with dextran/gelatin hydrogel was found to 
be a suitable substitute when both constituents where mechanically tested as 
independent layers 
(62)





2.3.2.3 Biological Properties  
Parallel to the mechanical analysis of these constructs, cellular response is often 
investigated in comparison with the individual components of the layered material. It 
is important to show that since this method could involve incorporating a polymer 
with a biological scaffold there is no statistically significant difference between the 
bilayer composite and a control group of pure biological component. As seen in a 
comparison between PLCL/Poloxamer nanofibers with dextran/gelatin hydrogel and 
plain dextran/gelatin hydrogel, there was no significant difference when the polymer 
was incorporated, indicating that the bilayer scaffold has no detriment on cell 
viability 
(62)
. Fortunately, several studies show improved cell viability, cell adhesion 
and proliferation, compared to polymer alternatives or control collagen sponges 
(28, 74)
. 
The porous nature of some composites, supported by an overall porous, or funnel like 





Perhaps more convincing of a scaffold’s benefit than unaffected viability is the 
potential to promote cell behavior towards reconstruction.  In an in vivo comparison 
after 180 days post implantation in a rat abdominal muscle injury, the ECM-coated 
polypropylene mesh showed decreased density of collagen and amount of mature 
type I collagen deposited between mesh fibers when compared to the uncoated mesh 
devices. This study confirmed and extends previous findings that an ECM coating 
supports healing and reconstruction of the injury site, and mitigates associated scar 
tissue deposition characteristic of polypropylene expected when used for ventral 




skin wound healing, resulted in better regeneration of dermal tissue and epidermis 
than either of the materials independently when evaluated in a nude mouse subdermal 
study (28). Other studies support this finding, citing the production of increased 
amount and specificity of matrix proteins by recruited cells on biohybrid materials 
when compared to the plain polymer alternative 
(45, 66, 68)
. 
2.3.3 Cell-Built ECM Layer Fabrication Method  
This method describes utilizing a cell population to lay down a tissue specific matrix 
on a polymer scaffold. When the cells are removed, the polymer scaffold is left with a 
bioactive ECM layer, prepared to host recruited cells. As described, this method 
could be an effective means to ensure complete inclusion of proteins based on cellular 
production, assuming the physiological niche can be appropriately simulated.  
This method appears to be more frequently used in bone and cartilage engineering 
applications 
(75)
, which are beyond the scope of this report. However, there has been 
promising results in soft tissue engineering applications as well. In a study by 
Shtrichman et al, an electropsun PCL/PLGA mesh served as mechanical support for 
cell seeding and ECM generation. By decellularizing the composite after a fixed time, 
the result is self termed an available "off-the-shelf" implantable product. This 
composite demonstrated biodegradability and biocompatibility in a rat subcutaneous 
model, and supported advanced cellular infiltration and habitation compared to 
uncoated PCL/PLGA scaffolds 
(76)
. Along similar lines, another study utilized a 
Vicryl knitted mesh made of polyglactin 910 (a 90:10 copolymer of glycolic acid and 
lactic acid (PLGA)), and cultured either mesenchymal stem cells, normal human 




PLGA mesh. When these discs were decellularized, they also showed promising 
results for supporting cell viability and ingrowth (28). In an in vivo study, a similar 
approach utilizing hMSCs to build a cell derived matrix within a collagen/HA 
scaffold showed excellent results in mimicking the bone marrow niche. ECM-Col/HA 
scaffolds formed less bone than Col/HA with or without hMSCs, suggesting the 




For some tissue applications, this method is perhaps the closest to reality if site-
appropriate cells can be cultured. However, the resources and time required to culture 
these cells could prevent this method from being a scalable procedure, and so far, 
success appears mostly in 2-dimensional constructs. Relying on cells to build an 
amount of ECM that would produce a significant, 3-dimensional layer could be 
challenging. It may be more feasible to obtain 3-dimensional scaffolds by designing 
the polymer base to support a 3D culture structure with pores or mesh. If a 
decellularizing technique could be developed that effectively removed cell fragments 
and other possible inflammatory debris, this method has the potential to add very 
specific ECM to geometrically relevant soft tissue implants.   
2.3.4 Materials Fabricated By Blending Hydrogel Components  
In this approach, presentation of site-specific proteins and extracellular matrix 
components are the main focus for the material. The objective of most design plans is 
to improve mechanical properties of biologically based matrices, and ensure retained 
cytocompatability. In order to alter mechanical properties, yet leave the natural 




material as structural components. Inert polymers are often chosen over the addition 
of other proteins to avoid disruption of the tissue specific composition of the ECM.  
 
2.3.4.1 Material Selection  
To create a cohesive and consistent material, a synthetic polymer network can 
physically and covalently incorporate a protein phase. In this way, ECM proteins are 
secured in 3D space without modification while the biological inert polymer serves to 
maintain consistent mechanical integrity and transport properties. As a bioinert and 
biodegradable material, the source of polymer component is most commonly 
poly(ethylene glycol) (PEG), or PEG with some modifications. PEG gels are often 
selected due to high water solubility, nontoxicity, low protein adhesion, and non 
immunogenitic properties 
(78)
. If modified through common techniques, PEG 
molecules can be functionalized using NHS and acrylate groups, for example, making 
them suited to chemically crosslink with side amine groups in ECM proteins.  
 
The source of the biological component in this fabrication technique is often either 
non-purified ECM homogenate, or artificially constructed ECM-like gel made from 
individual purified components. Non-purified ECM homogenate may more accurately 
emulate the microscale heterogeneity of natural ECM 
(57)
. As we have described, 
using regionally specific tissue has great effects on the incorporation of the tissue, and 
the inclusion of possibly unknown structural and chemical components could aid in 
tissue regeneration. It follows that the choice of tissue for this ECM homogenate 
should reflect the ultimate cite for the material. Popular choices include myocardial 








On the other hand, creating an ECM-based hydrogel from scratch by using building 
blocks with known concentration and composition can create a consistent material. 
These building blocks include collagen, elastin, glycosaminoglycan, as well as gelatin 
and chitosan. Gelatin, the partially hydrolyzed form of collagen, is not naturally 
present active ECM. However, in many respects including chemical structure, 
degradation mechanisms, and byproducts, can closely resemble its parent molecule 
collagen.  Modified gelatin (gelatin methacrylate) hyrdogels are a popular choice for 
the biological component in these scaffolds, combined with silk (81), PEG 
(82)
, PEG 
diacrylate (PEGDA) (32), chondroitin sulfate 
(83)




Blending of the materials requires optimization techniques based on unique properties 
of the hydrogels. In addition to the chemical crosslinking referred to above that 
utilizes functionalized PEG or gelatin, physical entrapment or freeze-thaw cycles to 
form cryogels are also possible techniques shown to produce evenly dispersed 
materials 
(84)
. By incorporating fibrillar type I collagen and reticular laminin, Jung et 
al were able to physically entrap these two ECM proteins within chemoselectively 
crosslinked PEG. The interpenetrating networks of these molecules were confirmed, 
and it was determined that the PEG component is capable of slowing degradation of 
the bulk material without chemically altering the proteins 
(60)
. In another example, silk 




ultrasonication to avoid harsh solvents or chemical crosslinking. The ultrasonication 
of silk and chitosan induce a conformational change of the silk from random coil to 
beta sheet. This results in the self-assembly of the hyrophobic peptide segments in the 
protein, entrapping chitosan chains in the silk networks 
(56)
. Freeze thaw cycles were 
employed by several groups to form cryogels of glycosaminoglycan-PEG 
(85)
, and 
ECM/PVA hydrogel. In this technique, scaffolds were created in a mold, with a thin 
ECM layer on top of the polymer solution. Freeze-thaw cycles are then introduced to 




A unique inclusion by Shin et al. highlights the possibility of one additional material 
characteristic, electroconductivity, otherwise unmentioned in the research compiled 
here. In this study, carbon nanotubes (CNT) were incorporated into gelatin 
methacrylate (GelMA) hydrogels. The composite material resulted in cardiac tissue 
constructs that showed excellent mechanical integrity, as well as advanced 
electrophysiological functions. Specifically, myocardial tissues cultured on 50 μm 
thick CNT-GelMA showed 3 times higher spontaneous synchronous beating rates and 
85% lower excitation threshold, compared to cells cultured on plain GelMA hydrogel. 
This parameter, it is discussed, is important when engineering tissues with 
particularly important conductive ability, such as heart muscle and nervous tissue 
(86).  
 
2.3.4.2 Mechanical Properties 
The driving reason to alter an ECM-based hydrogel is to incorporate additional 




made from matrix materials have been reported around 5-10 Pa at 1Hz (specifically 
from a gel formed from myocardial matrix) 
(80)
. The significant decrease from native 
heart muscle, in this particular example, can negatively affect cell adhesion, cell 
migration and signal transport. Mechanical comparisons, conducted by Christman et 
al., found that the addition of PEG to the hydrogel with either NHS, star PEG 
arcylate, or PEG diacrylate, significantly increased the storage modulus of the gel (5-
30 Pa in PEG NHS or PEG diacrylate, 719 Pa in the star PEG acrlyate system) over 
the ECM gel alone (5 Pa). The incorporation of PEG variations allowed for tunable 
degradation, with the ECM gel degrading two to three times faster than all of the 
hybrid variations. Cell studies indicate that adhesion and migration through 
myocardial matrix-PEG-NHS and acrylate hydrogels was possible, and that cells 




These results are echoed in studies investigating other combinations of materials.  An 
interpenetrating network of gelatin methacrylimide polymerized within a 
tetrafunctional PEG framework resulted in unique properties. Crosslinking ECM 
proteins within a synthetic matrix created a stable scaffold with tunable properties and 
with long term cell anchorage points supporting cell attachment and proliferation in 
the 3D environment 
(57)
. Cryogels of glycosaminoglycan-PEG were determined to 
have varied stiffness between the struts of the scaffold and the less stiff corresponding 
bulk hydrogel, suggesting this method can be utilized in design goals 
(85)
. This control 




material in compliant tissues may be limited. If the polymer component could be 
incorporated to a point that made it possible to attain tensile and elastic properties 
from the material, the composite could be used more broadly.  
 
2.3.4.3 Biological Properties  
In several studies, cell viability and function was seen to increase over the plain 
polymer controls. Cardiac cells improved cellular adhesion, organization, and cell–
cell coupling on CNT-GelMA compared to GelMA alone 
(86)
. Chondrocytes exhibited 
improved colonization and adhesion on ECM-PVA scaffolds compared with plain 
PVA as well as plain articular cartilage derived matrix, suggesting it is the 




Jung et al noted that hMSC viability was enhanced by the addition of exogenous 
ECM to PEG frameworks. In addition to viability, a glimpse of cell behavioral 
changes was observed in direct response to scaffold composition. For example, In the 
presence of exogenous laminin, hMSCs produced reticulate structures, as opposed to 
fibrillar masses in the presence of collagen I. In addition, miPSCs were able to form 
beating areas in composites containing no ECM, but to a lesser extent in composites 
containing either collagen I or laminin. Thus, the PEG-NCL approach provides an 
opportunity to independently examine the biochemical impact of ECM on stem cell 








As ECM-based biohybrid materials continue to be designed, an in depth analysis of 
immune response to the materials could provide illuminating information on the 
mechanisms that contribute to successful reconstruction. Moving beyond basic cell 
viability and material biodegradability, advanced studies can start to investigate and 
learn the complex role of the immune response to these scaffolds, and how that plays 
a role in long term functionality and constructive remodeling.  
 
Considering the complexity of the interaction between the immune response and 
other physiological systems, initial studies that have begun to look at this are 
providing a small taste of available knowledge. The majority of biohybrid materials 
investigated in this report are tested in animal models at their furthest point of 
investigation. Some earlier reports use histological techniques to identify “immune” 
cells from these sort of experiments.  Although this gives some measure of immune 
activation, it does not give any insights into the complicated and dynamic 
interactions. Additionally, evaluating the materials in immunosuppressed animals 
artificially removes elements that could significantly change the course of remodeling 
of the tissue (28). 
 
A large presence of foreign material can cause a foreign body response resulting from 
overlapping acute and chronic inflammation, and subsequent fibrotic and collagen 
encapsulation 
(87)
, which has historically been the assessment for “success” or 
“failure” of an implant. However, before that severe endpoint, there exists several 




events are not confirmed, one theory suggests that the foreign material will activate 
inflammasomes, which recruit macrophages as well as other leukocytes to the region 
to secrete additional signal and activate successive pathways (87, 88). Soon after 
arrival at the injured site, macrophages are expected to polarize, into a classic (M1) or 
an alternate (M2) phenotype (89). The classic phenotype is associated with 
inflammatory related events, including tissue destruction and activation of Th1 T 
cells. The alternate phenotype, on the other hand, stimulates healing events, including 
tissue remodeling and inflammatory cytokine suppression (89-91). Although it seems 
clear that activation towards an M2 phenotype in macrophages together with Th2 T 
cell activation would be desired, the interaction between the two activation pathways 
and local signaling events needs to be further investigated. An outline by Faulk 
suggests three mechanisms to include when studying this interaction. First to consider 
are the signals and environment created by the bioactive peptide fragments generated 
through scaffold degradation. Second, the recruitment of endogenous stem and 
progenitor stem cells to the site for ECM remodeling. And third, the modulation of 
the host macrophage response away from a proinflammatory phenotype, and towards 
an M2-TH2, pro-healing phenotype (72). 
 
Without intervention, ECM-based materials are most often degraded in vivo, and are 
associated with constructive tissue remodeling and minimal fibrosis (87, 89). As of 
yet, the specific cell signaling events by which ECM biomaterials modulate the host 
macrophage population toward a more constructive remodeling phenotype are not 




shown to influence the initial response of the immune system to prohealing, despite 
the polymer components that would be expected to individually illicit an 
inflammatory response (28, 44, 49, 92). The abdominal wall injury model comparing 
ECM-coated and uncoated polypropylene mesh devices showed that ECM coating 
decreased the inflammatory response as characterized by the number and distribution 
of M1 macrophages (CD86+/CD68+) around mesh fibers when compared to the 
uncoated mesh devices at 14 days post implantation (72). Furthermore, the local 
response was characterized as having less scar tissue, resulting from the ECM 
mitigated immune response.  Interestingly, other studies reference reduced fibrotic 
capsule (28), an indicator of reduced inflammation, and production of functional 
ECM (43, 49). Although these results do not provide insights into the intermediate 
steps, the end results do compel future studies on the material.  Expanding the 
understanding of how the immune system interacts with the implants can provide 
tools to assure or even manipulate healing of the implant.  
 
As an example, other studies investigating materials in subdermal implants have had 
success comparing the local cytokines belonging to either a Th1 (interleukin (IL) 2, 
interferon-γ) or Th2 (IL-4, IL-10, IL-13) profile. In a study comparing porcine dermal 
collagenous membranes to PTFE in Sprague Dawley rats, a higher ratio of Th1 
cytokines was found surrounding the porcine dermal tissue, where an increase in Th2 
cytokines was measured surrounding PTFE implants. This result agrees with the 
inverse relationship of the Th1/Th2 cell mediated and humoral immune response (90). 




provide new information regarding the intermediate steps in response to these 
materials.  
 
Crosslinking, or other altering steps to the natural tissue component, threatens to 
negatively impact this positive remodeling. Crosslinking or otherwise altering the 
tissue affects the functional design, manifested in changes to rigidity, porosity, 
insolubility and topography of the matrix. These characteristics determine the 
mechanical profile of each individual tissue (93, 94). Scaffold materials with 
chemical crosslinking agents may delay or prevent macrophage mediated 
degradation, but they also inhibit the formation of the M2-type response. The altered 
characteristics caused by crosslinking fibers result in decreased hydrophilicity and 
recognition of the scaffold, which can result in slowed cellular adhesion and 
proliferation in or near the scaffold. In fact, some crosslinked tissue shows resistance 
to cellular infiltration, and is characterized by a dense cell lining around the surface 
(63). The lack of healing and remodeling can result in downstream scar tissue 
formation and a persistent foreign body response (72).   
 
In a less drastic way, the choice to use gelatin instead of collagen could also affect the 
matrix presentation to cells. Gelatin, being chemically similar, but structurally 
different from collagen, does partially contribute towards unfamiliar environments in 
the form of physical recognition. In some cases, the comparison between gelatin and 
collagen in the same biohybrid scaffold shows significant differences in cellular 




a PLLA woven mesh, the PLLA–collagen scaffolds supported cells that more 
strongly promoted rebuilding ECM than did the PLLA–gelatin scaffolds (28). 
2.5. Conclusion 
A significant struggle in the development of tissue engineered constructs is 
remodeling and permanent maintenance by the body. This review considered the use 
of ECM-based biohybrid materials as tools to promote constructive remodeling 
through natural physiological functions. Keeping the scaffold as close as possible to 
the natural environment has been shown to significantly improve cellular infiltration, 
inhabitation, and constructive remodeling. Using natural tissue components is a direct 
way to incorporate natural signaling domains, recognition, attachment points to a 
scaffold. Incorporating polymer components can help recapitulate the bulk 
environment, which is also an important indicator of lasting success. Expanding the 
understanding of how the immune response interacts with the implants will help us 
determine how to use those systems to encourage success and integration of the 
scaffold. The quick recognition by native cells has been shown to be important in 
modulating immune response and contributing to lasting mechanical properties of the 
constructs.  
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Chapter 3: PPF Reinforced Pericardium as a Hybrid 
Material for Cardiovascular Applications2 
3.1 Introduction 
For more than 50 years, a method to replace malfunctioning or diseased tissue in the 
cardiovascular system has been an important area of development. Each year, over 
275,000 replacement valves and 600,000 vascular grafts are implanted to correct 
damaged native structures (17, 95). Complex pediatric and general cardiac surgeries 
also utilize tissue or synthetic patch material in reconstruction and repair. When 
considering materials for prosthetic applications, biological tissues offer some clear 
advantages over synthetic substitutes. Aside from the inherent biocompatibility, 
biological tissues possess “intelligent” elastic and mechanical properties that are 
unable to be mimicked by manmade material (96, 97). 
 
One biological tissue commonly used is pericardium. Pericardial tissue has 
historically been selected for cardiovascular devices due to its availability, inherent 
strength, and elastic properties. In addition to the desirable mechanical behavior 
described, natural tissue often demonstrates superior fluid dynamic properties, and 
when compared to synthetic materials, requires less anticoagulation therapy (97). 
                                                 
2
 Adapted from: L.G. Bracaglia,.L. Yu, N. Hibino, and J.P. Fisher. Reinforced pericardium as a hybrid 
material for cardiovascular applications. Tissue Eng Part A, 2014. 20(21-22): p. 2807-16. Reprinted 
with permission from TISSUE ENGINEERING Part A, Volume 20, Issue 21/22, 2014, published by 




In order to capitalize on and maintain the natural properties of pericardium, previous 
research has focused on improving the durability and biocompatibility of the material 
upon implantation.  However, and despite significant advances, clinical experience 
continues to highlight the challenges of the prolonged use of pericardium implants in 
the cardiovascular system(17).  
 
All natural tissue, including pericardium, can elicit an inflammatory and immune 
response from the host. To combat these inevitable events, pericardial tissue is 
commonly preserved in glutaraldehyde (GA), which chemically crosslinks the 
tissue’s collagen molecules. This crosslinking process is effective at stabilizing the 
tissue against chemical and enzymatic degradation, as well as lessening the display of 
antigenic determinants (8, 12, 98). However, the crosslinked product has been 
associated with local cytotoxicity and, more importantly, severe calcification of the 
material that can over time lead to subsequent matrix deterioration and compromised 
mechanical properties (10, 99, 100). 
 
The detailed pathways controlling calcification of cardiovascular tissue, both natural 
and prosthetic, are not explicitly understood, but as the most common pathology 
recorded in heart valve failures (16, 101), it is certainly a process under high 
investigation. It is observed that chemically crosslinking pericardium damages and 
distorts the natural structure, destroys interstitial cells, and diminishes potential for 
viable cell inhabitation (102). The specialized matrix consisting of collagen, elastin 




allowing the tissue to accommodate the constant changes in shape and stress transfer 
(102, 103), and is therefore essential to maintain. Damaging this natural structure and 
removing native cells results in a tissue that can no longer maintain or repair itself. It 
has been suggested in literature that calcification and eventual ossification is the 
result of insufficient or irregular repair of the tissue network.  In culture, 
myofibroblasts have been shown to undergo phenotypic differentiation into the 
osteoblast like cells seen in calcified cardiac tissue, promoting calcification and bone 
type remodeling (16).  Others suggest that the origin of bone cells in ossified valves 
in unknown, but their presence is confirmed in observation of excised heart valves 
and tissue (104). 
 
Original damage leading to the irregular repair of the implanted tissue can be a result 
of mechanical stress, immune cell infiltration, or other pathologies, which 
complicates the investigation of the process. In one theory, responding immune cells 
are reported to secrete collagenase, among other proteolytic enzymes, which 
immediately begin to degrade the collagen network (99).  It is further hypothesized by 
some that this initial proteolysis of crosslinked collagen debris creates foci for 
calcium deposition to initialize (30, 95, 100). Studies have shown a cooperative 
relationship between calcification of this type of tissue and the inflammatory 
response, enzymatic degradation, and microstructural failure (both independent 





Regardless of the mechanism directly controlling the calcium deposits, GA treatment 
has been shown through both in vivo and in vitro accelerated testing to destroy the 
surface endothelium of the tissue, autolytically disrupt interstitial cells, alter natural 
collagen bundles, and destroy native GAGS (15). Despite the discrepancies in origin 
of the deterioration, a strong correlation between GA treated tissue and increased 
calcification suggests that the chemical fixation of the tissue further inhibits the 
appropriate remodeling. 
 
The theory of calcification above suggests that if an alternative to GA can be 
developed that is effective at blocking enzymes and other immune activators, but 
avoids crosslinking of the tissue, then subsequent calcification of the material will be 
reduced. Our principal hypothesis is that applying a paintable polymer to the surface 
of pericardium tissue will provide the physical support and biological block to natural 
degradation, while leaving the original tissue unaltered. This will result in a hybrid 
material that will retain mechanical integrity but will not accumulate calcium 
deposits.  For this purpose, the synthetic polymer poly(propylene fumarate) (PPF), 
was selected for its demonstrated biocompatibility, biodegradability, and strength in 
other biomedical applications (105, 106). 
 
Poly(propylene fumarate), (PPF), is an unsaturated linear polyester that is 
crosslinkable through UV radiation with itself or with other compatible crosslinkers 
through the double bonds in fumarate.  PPF is biodegradable by hydrolysis of ester 




glycol upon degradation (107).  The degradation time is largely dependent on 
polymer characteristics such as molecular weight, crosslinker, and crosslinked density 
(107). The uncrosslinked polymer is viscous at room temperature, allowing it to be 
easily “painted” onto a surface.  In addition, PPF viscosity can be reduced, without 
significantly altering the components of the system, with the addition of diethyl 
fumarate (DEF), the monomer from which PPF is synthesized.  The addition of DEF 
to PPF can also cause variations in the crosslinked biomaterial’s mechanical strength, 
and can be utilized as a parameter to tune the characteristics of the hybrid biomaterial 
(108). 
 
To address our overall hypothesis, the first aim was to identify measurable 
mechanical properties of natural pericardium and develop a composition of PPF to 
mirror those properties. The designed composition of the polymer was then married 
to the pericardium tissue, and the hybrid material was evaluated on two fronts. The 
first evaluation of the hybrid material was to test if PPF reinforcement was an 
effective support for natural pericardium enzymatic degradation. The second 
evaluation of the hybrid material was to investigate if PPF reinforced pericardium 
would cause minimal calcification when compared to the GA treated standard. 
Performance in these two areas will support the hypothesis that a topically applied 






3.2.1 Polymer Synthesis and Composition  
PPF was synthesized by a two-step process as previously described (109). Briefly, 
propylene glycol and diethyl fumarate were combined in a 3:1 molar ratio. Zinc 
chloride, acting as a catalyst, and hydroquinone, as a radical inhibitor, were added in 
a 0.01:0.002 molar ratio. The reaction was carried out under nitrogen flow, producing 
ethanol as a byproduct and bis(hydroxypropyl) as the intermediate. Next, under 
vacuum, transesterifcication of the intermediate produces PPF with propylene glycol 
as a byproduct. Gel permeation chromatography was used to calculate the number 
average molecular weight (Mn) and polydispersity index (PDI) of the purified PPF. 
For use in this study, PPF (Mn 1150 and PDI 1.6) was mixed with the monomer DEF, 
and then mixed with the photoinitiator bis(2,4,6-trimethylbenzoyl) phenylphosphine 
oxide (BAPO), to create a UV sensitive reaction. 
 
To select the ratio of polymer to monomer that would be a suitable match for 
pericardium material, a set of weight to weight ratios of PPF to DEF was tested in 
thin-film formation, as shown in Figure 3.1A.  Soluble fraction of the crosslinked 
composite was measured comparing the dry mass of the film to the dry mass after 
soluble components were dissolved in acetone for 12 hours, using the following 
equation:  
𝑆𝑜𝑙𝑢𝑏𝑙𝑒 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 % =
𝑚𝑖𝑛𝑖𝑡𝑖𝑎𝑙 − 𝑚𝑓𝑖𝑛𝑎𝑙
𝑚𝑖𝑛𝑖𝑡𝑖𝑎𝑙




3.2.2 Mechanical Testing of Polymer Compositions  
PPF composite films as previously described were tested on an Instron for mechanical 
analysis using ASTM D638 to obtain 0.1% yield strength and elastic modulus. Thin-
films were formed between two 2x2 cm square glass plates, and resulted in 0.25 mm 
thick, 0.15 g films (Figure 3.1B). This geometry is similar to the weight per surface 
area approximated for coating pericardium, as well as a suitable shape for testing 
according to ASTM D882. Extension rate was set at 10mm/min, and extension and 
corresponding load was recorded at a frequency of 10 Hz. A preload of 5 N was 
considered. Elastic modulus for each sample was calculated using MATLAB to 
determine the slope of the linear region of the stress-strain curve reported by the 
Instron. The linear region of the curve was systematically calculated using linear line 
fit command based on the first 10 data points. The program then continued to add 
data points in steps of 10 until the R
2
 < 0.97. The slope of this region was determined 
to be the modulus of the sample. Strength at 0.1% yield was calculated as the 
intersection of the stress-strain curve with a line drawn parallel to the linear slope, 
whose x-axis intercept is shifted 0.01 mm/mm strain. 
3.2.3 Sample Preparation  
Throughout this study, PPF reinforced pericardium was compared to GA treated 
pericardium and untreated pericardium as controls. All pericardium was obtained 2 
days after harvest from Innovative Research, Inc. and stored at 4 °C in physiological 
saline. Experiments were conducted within 2 days of receiving the pericardium, and 
because the properties of pericardium are thought to vary among individual donors, 





Glutaraldehyde treated samples were prepared by immersing small strips of 
pericardium (2 x 6 cm) in a 0.625% GA solution for 6 hours at room temperature. 
Samples were then washed twice and stored in saline at 4 °C. PPF reinforced samples 
were also cut into 2 x 6 cm strips, and were lightly stretched onto wooden frames to 
maintain spatial conformation. The tissue was then dehydrated in ethanol dilutions, in 
order to facilitate the interaction and integration of hydrophobic PPF with 
pericardium and remove antigenic determinants.  Dehydrated pericardium was then 
coated with a thin and uniform layer of PPF to completely cover the tissue strip. The 
coated tissue strip was then exposed to UVa light for 90 minutes (3.5 mW/cm
2
) to 
crosslink the polymer. After crosslinking, tissue and polymer composite were 
rehydrated in physiological buffer at room temperature for 2 hours, and then stored in 
4 °C. Pericardium samples from each group were mechanically tested using the 
method described previously as controls. 
3.2.4 In vitro Evaluation- Degradation Test  
An in vitro degradation model was designed to investigate the added strength and 
resiliency of the PPF reinforcement as compared to untreated pericardium and GA 
treated pericardium as controls. Pericardium samples were exposed to 0.4 U/mL of 
collagenase, and shaken at 60 RPM in 37 °C. The test was run over a period of 12 
days, with mechanical analysis testing performed every 4 days (n=8 per day), as 





3.2.5 In vitro Evaluation- Calcification Test  
To compare in vitro calcification between PPF reinforced and GA treated 
pericardium, samples from these groups were exposed to physiological calcium 
buffer (2.6 mM calcium/1.6 mM phosphate) at 37 °C, for a total period of 45 days. At 
each time point (5, 12, 21 days), 15 samples from each treatment group were isolated 
for analysis. For each treatment group, eight of the isolated samples were reserved for 
mechanical analysis, which was performed as previously described. Two of the 
samples were preserved for histological study. The final 5 samples were used to 
quantify calcium deposition. These samples were first triple washed in deionized 
water to remove loosely attached calcium, and then oven dried at 80 °C for 6 hours to 
measure dry mass. Samples were then hydrolyzed in 2M HCl for 48 hours to dissolve 
calcium deposits on the tissue. Solutions were then measured for calcium 
concentration using a colorimetric assay. Calcium concentration at each time point 
was statistically compared using a student’s T test. 
3.2.6 In vivo Evaluation  
Calcification rate and material integrity of the hybrid material were evaluated in a 
subdermal rat model. The Institutional Animal Care and Use Committee of the 
University of Maryland approved the study, and all animals were treated in 
accordance with the “Guide for the Care and Use of Laboratory Animals”. The 
experiment was conducted in n=16 male Sprague Dawley (SD) rats, as determined by 
a power analysis. As seen in literature for material analysis (110), a small incision is 
made in the dorsal dermal layer, and a material patch (1 x 1 cm) from each of the 




points of 3 weeks and 6 weeks, n=8 animals were euthanized and the pericardium 
patches and surrounding tissue were explanted. Each explanted tissue sample was 
carefully sliced in half. One half of each sample was preserved in paraformaldehyde 
(4%) and embedded in paraffin for histological analysis to determine calcium 
deposition, cellular population and resulting tissue morphology, and inflammatory 
response.  
 
Inflammatory response in particular was investigated using immunohistochemistry to 
stain for the presence of the macrophage cell surface antigen F4/80. Slides were 
incubated with PEROXIDAZED1 (Biocare, Concord, CA), an endogenous 
peroxidase blocker, and BackgroundSNIPER1 (Biocare), a broad spectrum blocking 
reagent. The samples were then incubated with anti-F4/80 (rabbit polyclonal to F4/80, 
abcam ab74384) as the primary antibody, followed by a biotinylated anti-rabbit IgG 
as the secondary antibody (Vector laboratories). Using a horseradish peroxidase-
streptavidin system, followed by a 3,3’-diaminobenxidine tetrahydrochloride 
chromagen, the presence of the F4/80 molecule was detected. All samples were then 
counterstained with hematoxylin. Macrophage population was determined through 
examining 3 standardized images from each of n=5 samples per treatment group. 
Macrophage fraction was defined as the number of cells determined to have F4/80 
staining divided by the total cells counted per image in a blinded study. Data is 
presented as an average of each of these fractions, and error was calculated as the 





The other half of each sample was dried in a 60 °C oven 18 hours, and then 
hydrolyzed in 2M HCl for 48 hours. A colorimetric assay was used to determine 
calcium concentration of each sample. 
3.2.7 Statistical Analysis 
All quantitative assessments were statistically compared using a one-way ANOVA 
test, (p<0.05), followed by a post hoc Tukey’s test, unless otherwise noted. 
3.3 Results 
We have developed a biohybrid material that consists of a polymer reinforcement 
later painted on the natural biomaterial pericardium. The mechanical characteristics 
of the polymer directly affect those of the hybrid material, and were therefore the 
determining factor in selecting a polymer composite. Following mechanical analysis 
of the thin-films composed of different formations of PPF: DEF ratios, the 2:1 
dilution was selected for future work. The yield strength of this composition (5.48 ± 
2.27 MPa) was found to be the greatest, and therefore the closest to the tested values 
for untreated and GA fixed pericardium (11.32 ± 4.24 and 13.01 ± 4.35 MPa, 
respectively). A comparison of yield strength and modulus of the thin-films is shown 
in Figure 3.1C. The modulus of elasticity and yield stress of pericardium is known to 
vary between donors based on age and other physiological features, but the values 
exhibited by the 2:1 films in elasticity measurements are sufficiently high to support 





Figure 3. 1 PPF Thin Film Analysis. The compositions of Various Thin Films Tested, listed as mass 
to mass ratios of PPF to DEF (A), were crosslinked into thin films from the same total volume (B). 
Resulting thin films were 0.25 mm thick and weighed 0.15 grams. The image in B shows a thin film 
composed of 2g PPF to 1g DEF (2:1). Elastic modulus and 1% yield strength of thin films (C) were 
tested on an INSTRON mechanical tester, and extended at 10mm/min by a 50 N load cell. n≥7 for all 
groups, ANOVA statistical test shows significant difference, (p<0.05), and Tukey’s Post Hoc results 





Figure 3.2A displays mechanical analysis data from untreated pericardium from three 
separate donors, as a reference. The soluble fraction of thin sheets of 2:1 PPF to DEF 
was calculated as 13.3 % ± 2.7%, (n=9). 
 
As mentioned, the 2 PPF: 1 DEF composition was selected for further evaluation in 
the hybrid material model. After physiological degradation in vitro, mechanical yield 
strength and elastic modulus of PPF reinforced pericardium are not significantly 
different than the gold standard GA treated pericardium, (α=0.05), (Figure 3.2C). By 
day 8, the strength and elasticity of both of these materials still remains above 11.5 ± 
3.42 MPa 0.1% yield strength and 54.00 ± 12.67MPa elastic modulus. These values 
are comparable to the untreated control on day 0, measured at 12.34  ± 1.49 and 58.80 
±  10.17 MPa, respectively. However, by day 8, the untreated sample has fallen as 
low as 2.91 ± 0.80 MPa and 20.29 ± 7.76 MPa. These results of reduced or 
maintained material strength are supported by observations from histological 
photographs of the pericardium samples, which contrast a highly disordered fresh 
pericardium fiber network with a more ordered and dense PPF reinforced pericardium 






Figure 3. 2 In vitro Analysis of PPF Reinforced Pericardium. The graph displays the physical 
properties of pericardium from 3 different donors (n=8 per donor) (A). Yield strength and modulus 
were evaluated from samples over an in vitro degradation simulation using collagenase (n=8 per time 
point) (C). ANOVA statistical tests showed significant difference in the elastic modulus and in the 
thicknesses (p<0.05), and results from a post hoc Tukey’s Test are shown on the graphs. Groups that 
do not share a letter are significantly different. The control on Day 0 has no PPF reinforcement or 
collagenase exposure. Control groups on the following days are exposed to collagenase but not 
reinforced with PPF or treated GA. After degradation, samples were fixed and stained using 
hemotoxylin and eosin to display structure of collagen network (B). Control pericardium appears to 
have lost structural integrity after collagenase degradation (d), as did the EtOH dehydrated sample (c), 
while the sample with PPF reinforcement (b) appears unaltered from the natural pericardium (a). In 




quantified (n=5 per time point). A students T test shows significant difference between the calcium 




In addition to mechanical property retention, calcium deposition was also evaluated in 
vitro. The time dependent graph in Figure 3.2D displays calcium deposition onto GA 
treated and PPF reinforced tissue from an in vitro calcification model. The level of 
calcification of GA treated tissue is significantly higher than the level of calcification 
of PPF reinforced tissue at each time point (except day 0), (p<0.05).  Mechanical data 
did not show any distinct differences between groups. 
 
Calcification was next further evaluated in the in vivo model. Calcification of PPF 
reinforced pericardium was significantly less than GA treated samples in the 
quantitative assessment (p<0.05) at each time point. The graph in Figure 3.3B shows 
calcium deposition per mass of dried tissue weight compared between the three 
experimental groups. These results were confirmed by the Von Kossa histological 
stain (Figure 3.3C), in which calcium phosphate depositions are observed in GA 
treated samples on week 3 and 6, but little to no staining is observed on PPF 
reinforced samples or on untreated samples. The staining in these last two groups 
appears unchanged from the un-implanted controls (day 0), a result that is confirmed 
by the maximum variance of ±1 µg of calcium /mg of tissue from the day 0 level over 
the 6 week period.  
 
In histological samples stained with Masson’s trichrome (Figure 3.4A), we observe 
that PPF reinforced tissue remain intact up to 6 weeks, with regions of cellular 
infiltration. GA treated tissue appears to have limited cell movement into the 




Furthermore, GA treated pericardium is observed to exist in a dense network. We 
further observed untreated tissue was difficult to identify as a distinct material within 
the surrounding tissue.  
 
Using immunohistological staining techniques, it was confirmed that cells expressing 
the F4/80 surface molecule, a known marker of macrophages, are present at or near 
the implanted tissue in all treatment groups (Figure 3.4B). Regions of tissue with 
dense cell packing also present high amounts of F4/80 stain. In particular, it was 
observed that the dense cell line seen near the edge of the GA treated tissue has a high 
presence of F4/80 stain. This is also observed in the other tissue samples, but in small 
pockets and dispersed throughout the implanted region and neighboring soft tissue. 
Macrophage fraction of the total cell population in each sample is displayed in Figure 
3.4C. This fraction is greatest in GA treated samples, 36.3 ± 18.7% of the population, 
and is followed by the untreated samples at 29.0 ± 12.4%, and finally by the PPF 





Figure 3. 3 Calcification of Pericardium Samples from In vivo Subcutaneous Model. Calcium 
content was quantified on samples explanted after 3 and 6 weeks, and compared to non-implanted 
controls (n=8 per time point) (C). Calcium content from each sample group was compared for each 
time point using an ANOVA test (p<0.01). A post hoc Tukey’s test showed significant difference in 
the GA-treated group, as denoted “*”, (p<0.05).  Samples were also fixed and prepared for histological 
analysis using Von Kossa stains. The dark black region indicates calcium phosphate deposits. This 
region is seen significantly darker in GA treated samples after 3 and 6 weeks of implantation, and not 






Figure 3. 4 Histological Analysis of Explanted Pericardium Samples. Cellular response to 
implanted samples was analyzed using Masson’s trichrome stain (A). Blue regions indicate collagen, 
pink indicates cell bodies. Staining shows local cell populations relative to implanted tissue. Cell 
populations in the region of the implanted tissues were also stained for F4/80, a macrophage surface 
marker (B). Staining shows a correlation between dense cell regions and the F4/80 stain, indicating an 




while in the PPF reinforced and untreated samples, macrophages are seen in smaller regions 
throughout the sample. On the other hand, there was no significant F4/80 expression in Day 0 samples 
(B.A) and samples lacking the primary antigen from week 6 (B.B). A rat spleen stained by the same 
procedure is shown in B.C as a positive control. Macrophage population was investigated by 
examining 3 standardized images from each of n=5 samples per treatment group. Macrophage fraction 
was defined as the number of cells determined to have F4/80 staining divided by the total cells counted 
per image in a blinded study. Data is presented as an average of each of these fractions, and error was 
calculated as the standard deviation between all images in each group. Population fractions from the 
GA treated samples and the PPF reinforced samples are significantly different, as determined by a one 
way ANOVA test, followed by a post hoc Tukey’s test (p<0.05). Groups that share the same letter are 





3.4 Discussion  
Utilizing pericardium as a naturally strong and elastic biomaterial offers clear benefits 
for building cardiovascular devices. In order to utilize pericardium’s strengths for a 
cardiovascular implant, steps need to be taken to preserve the tissue in a foreign body 
environment. Glutaraldehyde treatment is effective at preventing degradation of the 
collagen network and preventing immune cell infiltration by crosslinking the collagen 
fibers. However, this process renders the tissue non-viable, which forces the body to 
resort to unnatural healing mechanisms to repair inevitable fractures and defects in 
the tissue. In this process, the natural mechanical properties and hemodynamic 
capabilities are lost or altered. 
 
To combat the issues caused by GA fixation, strategies that target either therapy with 
anticalcificaiton agents or biomaterial modifications are among approaches 
commonly investigated. Biomaterial modifications focus on improving or modifying 
the GA fixation through altering the reactivity or concentration of the chemical, or 
using an altogether different chemical process. This last route has included options 
such as epoxy compounds, carbodiimides, and acyl azides, which all eliminate the use 
of GA, but still hinge on a chemical crosslink of the tissue. Some of those methods 
have shown successful results in the laboratory, but have had little translation into 
clinical practice (17).  
 
In this study, it was hypothesized in this study that a thin coating of PPF would 




completely avoiding alteration of the tissue though the use of chemical crosslinker, 
result in a less calcium deposits. 
 
As demonstrated initially in in vitro degradation, PPF reinforced pericardium did not 
lose mechanical strength (yield strength or elastic modulus) after collagenase 
exposure. In fact, the retained elastic modulus and yield strength was not significantly 
different from the gold standard control (GA treated). This retained strength as 
demonstrated in mechanical testing and retained physical structure observed in 
histological images support the superior durability of PPF reinforced pericardium 
when compared to the untreated control in a physiological model. This indicates a 
thin layer of PPF is successful at protecting pericardium from structural deformation 
due to enzyme activity. This claim is supported further by results from the sub dermal 
model. The rapid loss in strength and observed loss in organization of natural 
pericardium is visually and statistically distinct from the PPF reinforced and GA 
treated pericardium after enzymatic degradation. 
 
Furthermore, the inflammatory response characteristics differ between the PPF 
reinforced and GA treated cases, as observed with immunohistochemical staining for 
macrophage presence. In addition to overall lower total macrophage density in PPF 
reinforced samples; macrophages are homogenously spread throughout the implant. 
In GA treated samples macrophages are seen in a distinct and dense cell line 





More importantly, the calcium deposition in the reinforced pericardium was 
significantly less than the GA treated samples in both the in vitro and in vivo models. 
The accumulated calcium on the PPF reinforced samples was in fact so low that is 
was not significantly higher than either the untreated samples or any of the un-
implanted day 0 samples. This result suggests that the calcium deposits are not 
necessarily related to implanting xenographic tissue, but agrees with the theory that 
detrimental calcium deposition seen on GA treated implants is related directly to the 
crosslinking of the tissue. By eliminating the crosslinking component, we have 
demonstrated an approach that could block calcification of implants before the 
unnatural healing mechanism starts.  
 
As we have shown here, the process of dehydrating and coating the pericardium with 
the biocompatible polymer PPF interacts with the extracellular matrix in a physical 
and not chemical or otherwise transformative way. Histological images in Figure 10 
display cellular infiltration from the edges of the samples, indicating that PPF 
reinforcement leaves the protein matrix suitable for cell viability. These observations 
can be directly compared to GA treated samples, where little to no cells have 
migrated into the tissue. This difference suggests that PPF crosslinks into a network 
on the surface of the pericardium that is mechanically linked in the surface network of 
proteins, and does not disturb the natural composition. This alternate outcome from 
the processing of pericardium may explain why the PPF reinforced pericardium 
appears to retain more original structure (Figure 3.4A), as compared to the dense 




significant calcium deposits. Overall, the results presented support that the innovative 
and unprecedented combination of a synthetic polymer with a natural biomaterial 
may avoid the detrimental end points of GA treated pericardium.  
3.5 Conclusion  
We have established for the first time a hybrid material that preserves the natural 
properties of pericardium and adds support with a biocompatible polymer, while 
avoiding crosslinking of the tissue. We have shown that the pericardium composite is 
protected against enzymatic degradation by the paintable application of the polymer, 
and that the addition of this polymer causes less calcification than the GA treated 
pericardium. Calcification of cardiovascular devices remains a forefront of concerns. 
The lower amount of calcium deposition on PPF reinforced pericardium is an 
important improvement when compared the GA treated calcium accumulation. These 
results suggest that PPF can be applied to reinforce pericardium instead of 
glutaraldehyde treated tissue, which is habitually used despite its dangerous and 
inevitable failure. By eliminating crosslinking with GA, not only would this fate be 
avoided, but the probability of improved healing and maintenance of the injured or 
diseased state would be gained.  A material with lowered calcification rate would 
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Chapter 4: Inflammatory Response to PPF Reinforced 
Pericardium in a Rat Model 
4.1 Introduction  
Materials for vascular grafts and patches are essential tools for aneurysm repair, 
vascular reconstruction, and congenital heart disease treatment (18, 111). Tissue 
engineering strategies applied to vascular material development strive to create an 
implant that will support ingrowth and maintenance from a patient’s own tissue, 
leaving behind functional vasculature when the implanted scaffold slowly degrades 
away. To be successful in this application, scaffolds need to fulfill a number of broad 
functions, both in mechanical behavior as well as complex biological remodeling. 
New approaches to vascular grafts and patches attempt to utilize the inherent immune 
reaction to implanted material to harness the patient’s natural healing capabilities, and 
then ultimately use those capabilities to develop the new tissue (112).  
 
Extracellular matrix (ECM) based scaffolds are being developed to harness the 
immune reaction and natural healing capabilities (113). The constituents of ECM 
make it biologically active, with the potential to provide tissue specific environmental 
cues (23, 114). Specifically for vascular tissue, unique ratios of collagen types, 
elastin, and other proteins can stimulate distinct cell populations such as endothelial 
cells and smooth muscle cells that are required in the functional development of 
vascular tissue (21, 115). In addition, many applications of ECM-based scaffolds 




compared to synthetic scaffold controls. The temporal polarization of arriving 
macrophages could be a significant determinant of the healing path followed by other 
cells (116, 117). An M1 phenotype is often involved in phagocytosis of debris, 
recruitment of other immune cells, and signaling for new matrix production and 
proliferation of fibroblasts and other cells (118). These actions are beneficial in initial 
wound repair, but can become pathogenic if they continue to propagate, leading to 
fibrous capsule formation, rapid deterioration of the scaffold, and stenosis in the 
vicinity. On the other side of the spectrum are M2 macrophages, which are 
responsible for cytokines that can stabilize new endothelial layers, reduce 
inflammatory cytokines, and support endothelial cell proliferation (119).  
 
The effect of ECM on the activation and polarization of macrophages can have 
immense benefits as the new vascular tissue develops, either in propagating 
inflammation or stabilizing new tissue formation (120). Creating a scaffold that 
induces the right balance of macrophages and ratio of scaffold destruction to tissue 
rebuilding could have a big impact on outcome of the injured site. The macrophage 
activation in response to a hybrid biomaterial is an important indicator of the potential 
outcome both in terms of endothelialization and chronic inflammation (118, 121). 
Macrophages that sustain an M1 phenotype may impedes the initiation of the 
remodeling phase. An M1 phenotype after 6 weeks may indicate the formation of a 





In Chapter 3, we reported on the biohybrid material, poly(propylene fumurate) (PPF) 
reinforced pericardium, as a scaffold for vascular wall repair (63). This material 
combines the bioactivity of pericardium, a matrix-dense tissue found surrounding the 
heart muscle, with the strength of the polymer PPF. In this previous chapter, we 
demonstrate that the polymer reinforcement is as effective as the chemically 
crosslinked alternative (glutaraldehyde, (GA)) at preventing detrimental weakening 
due to enzymatic degradation upon implantation (Figure 3.2). More importantly, the 
polymer reinforcement results in significantly lower calcification of the pericardium 
than chemical crosslinking in a rat subdermal implant after only 3 weeks (Figure 3.3). 
Changes in calcification could be explained by unnatural healing in response to 
eliminated or masked active components of the pericardium due to chemical 
crosslinking (63). Furthermore, immunohistochemical staining for the F4/80 surface 
antigen showed significantly less macrophages (p<0.05), quantified as a percent of 
total cell population, surrounding the PPF reinforced pericardium (18.2 ± 8.0% of the 
population) compared to GA (36.3 ± 18.7%) or untreated pericardium (UN) (29.0 ± 
12.4%) (Figure 3.4) (63).  
 
In addition to macrophage presence, the PPF reinforced tissue caused moderate cell 
infiltration, indicating a “middle road” between rapid scaffold deterioration in the 
untreated case, and capsule formation around the GA pericardium. These results 
suggest that the PPF layer could be responsible for controlling the presentation of the 




components, but eliminating the risk of rapid degradation and propagation of 
inflammatory cycles.  
 
The work presented in this chapter aims to understand and capitalize on the addition 
of a synthetic component to control the inflammatory response and eventual 
rebuilding of the tissue implant. The objectives of this study are to first characterize 
the immune response in terms of extent (number of responders) and macrophage 
phenotype after 6 weeks of implantation from the pericardium scaffolds in 
immunocompetent rats. Second, in order to use PPF as a tool to leverage presentation 
of the ECM molecules, the isolated effect of an incremental increase in amount of 
polymer and degradation products in relevant cell groups, leukocytes and endothelial 
cells. Finally, the polymer:ECM ratio is repeated in a subdermal study in athymic 
rats. This experiment will target a macrophage dominated response, and provide an 
isolated look at the macrophage population. We hypothesize that increasing the 
amount of polymer, and therefore decreasing the concentration of ECM that is 
exposed without complete masking with chemical crosslinking, will reflect a healing 
and anti-inflammatory environment from responding macrophages.  
4.2 Methods 
4.2.1 Material Synthesis  
The polymer PPF was synthesized following previously published methods (109). 
Briefly, propylene glycol and diethyl fumarate were combined in a 3:1 molar ratio. 
Zinc chloride (catalyst) and hydroquinone (radical inhibitor) were incorporated in a 




byproduct and bis(hydroxypropyl) as the intermediate. Transesterification under 
vacuum of the intermediate produces PPF with propylene glycol as a byproduct. Gel 
permeation chromatography was used to calculate the number average molecular 
weight (Mn) and polydispersity index (PDI) of the purified PPF. For use in this study, 
PPF (Mn 1150 and PDI 1.6) was mixed with the monomer DEF in a 3:1 ratio and 
then mixed with the photoinitiator bis(2,4,6-trimethylbenzoyl) phenylphosphine oxide 
(BAPO), to create a UV sensitive reaction. The polymer at this phase can be 
crosslinked to a solid, thin film with UV light (3.5 mW/cm
2 
) for 45 minutes.  
 
The PPF pericardium hybrid was created as developed as described in Chapter 3 (63). 
Briefly, fresh bovine pericardium was obtained 2 days after harvest from Innovative 
Research, Inc. and cut into strips 2x6 cm for dehydration. A liquid layer of PPF:DEF 
as described above was applied either as a single layer on the surface or on both sides 
of the tissue, and the combined material was exposed to UV radiation for 45 minutes 
(3.5 mW/cm
2
) to crosslink the polymer. This method was used to create samples for 
PPFSD (both sides), 2PPFAthymic(AT) (both sides), and 1PPFAT (one side). The hybrid 
material is then cut to 1x1 cm squares, washed in sterile 70% ethanol for 6 hours, and 
then rehydrated fully in sterile PBS for 12 hours.  
4.2.2 In vitro Studies   
Primary splenocytes were isolated from the spleens of male Sprague Dawley (SD) 
rats. Spleens were aseptically removed from the animal and pressed through a 60-μm 
nylon mesh in RPMI-1640 medium. The cells washed and re-suspended in RPMI-




100 μg/mL streptomycin. PPF thin films were added to the splenocyte culture on the 
day of isolation (day 0). Control groups were created using 100ng/mL 
lipopolysaccharide (LPS) as an activator. After 3 days, cells were collected via cell 
scraping and stained for surface marker analysis.  
 
Splenocytes were fixed and permeabilized following procedures recommended for 
antibody use from BioRad. Briefly, cells were fixed with 0.1% PFA for 15 minutes, 
and then permeabilized using 0.5% Tween. Cells were stained with anti-CD68 (a 
general macrophage marker), anti CD163 (expressed intracellularly on M2 
macrophages) and anti CD80 (expressed intracellularly on M1 macrophages). For 
each cell sample, 20,000 events per test were analyzed using a BD FACSCanto II 
flow cytometer.  
 
Human umbilical vein endothelial cells (HUVECs) were cultured in endothelial basal 
media (EBM) supplemented with EGM SingleQuot Kit Supplements and Growth 
Factors (Lonza, Walkersville, MD). All cells were used at or below the 4
th
 passage. 
To determine behavior changes to HUVECs in response to the PPF, PPF thin films 
were created as described, and washed to remove uncrosslinked polymers. Films were 
combined with EGM media, and incubated for 0, 3 and 5 days to create 3 stages of 
hydrolytically degraded states. The films or media containing the degraded products 
were added to HUVEC culture for 6 hours. RNA was isolated from HUVECs using 
an RNeasy Mini Plus Kit (Qiagen, Valencia, CA) following standard procedures. 




Reverse Transcription Kit (Applied Biosystems). Glyceraldehyde-3-phosphatase 
dehydrogenase (GAPDH) was used as an endogenous control gene for all samples.  
 
Gene expression assays were combined with the cDNA from each sample and 
TaqMan PCR Master Mix II (Applied Biosystems). The reaction was conducted on a 
7900HT real-time PCR system (Applied Biosystems) using thermal conditions of 2 
min at 50 °C, 10 min at 95, and 40 cycles of 15 seconds at 95 and 1 min at 60. The 
relative gene expression level of each target was normalized to the mean of the 
GAPDH level, and then fold change was calculated using the ΔΔCT method. Samples 
were completed in triplicate and the standard deviations are reported.  
4.2.3 In vivo Studies  
In vivo analysis was conducted in both SD and athymic adult, male rats. The protocol 
was approved by the Institutional Animal Care and Use Committee of the University 
of Maryland, and all animals were treated in accordance with the “Guide for the Care 
and Use of Laboratory Animals”. The first experiment was conducted in n=5 SD rats, 
as determined by a power analysis. A small incision is made in the dorsal dermal 
layer, and a material patch (1 x 1 cm) from each of the following three groups was 
sutured by the corners to the underlying tissue: GA crosslinked pericardium (GASD), 
untreated pericardium (UNSD), and PPF reinforced pericardium (PPFSD). After 6 
weeks animals were euthanized and the pericardium patches and surrounding tissue 
were explanted, preserved in paraformaldehyde (4%), and embedded in paraffin for 




The second study was conducted in n=5 athymic rats. Following a similar procedure, 
one material patch from each of the following groups was implanted subdermally in 
the dorsal dermal layer: untreated pericardium (UNAT), pericardium with PPF on both 
sides (2PPFAT) and pericardium with PPF on one side (PPFAT). Material was 
explanted after 6 weeks. Half of each explant was fixed in paraformaldehyde (4%) 
and embedded in paraffin for histochemical analysis. The other half of each material 
was homogenized and analyzed using a TNFα ELISA (Qiagen).  
 
Paraffin embedded samples were sectioned into 5 μm slides and stained using 
hematoxylin and eosin (H&E) to assess remodeling and total cell infiltration. To 
quantify the cell density near the implanted material, a midline was drawn down the 
center of the original material volume using Image J. Parallel lines were placed at 100 
um intervals from the center. Macrophages were identified using following antibody 
and fluorophore pairs: a mouse anti-CD68 antibody (Abcam, 1:100) and goat anti-
mouse FITC conjugated secondary antibody (Abcam, 1:200), a rabbit anti-CD206 
antibody (Abcam,1:600) and a donkey anti-rabbit Alexa Fluor®647 secondary 
(Abcam, 1:200), a goat anti-CD86 antibody (Novus Biologics, 1:200) and donkey 
anti-goat Alexa Fluor®555 secondary (Abcam, 1:200), and a cell nucleus stain 
VectaSheild® plus 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) (Vector 
Laboratories).  
4.3 Results and Discussion  
Biomaterial implantation into SD, immunocompetent rats results in distinct 




mediated remodeling of the pericardium. In Figure 4.1A, we can see initial 
differences in the material due to treatment methods. GASD treated tissue is tightly 
ordered, and exists in dense waves. PPFSD reinforced pericardium is less tightly 
packed, resembling more the flexible structure of untreated pericardium. After 6 
weeks in vivo, representative images with H &E staining highlight host cells that have 






Figure 4. 1 Subcutaneous Implants in Sprague Dawley Rats. Representative images (A) of the 
scaffolds before implantation are stained with H&E to show matrix organization and structure 
differences. The layer of PPF is visible in the top row using phase contrast microscopy. After 6 weeks 
of implantation, scaffolds are explanted and stained with H&E (B), showing cell infiltration (nuclei are 
purple) and matrix changes compared to the un-implanted images (A). Using immunohistochemical 
staining, cells near the scaffold were identified as macrophages using CD68, and further characterized 
using CD86 (an M1 marker) and CD206 (an M2 marker). Scale bar is 20 μm, unless otherwise 




 Cell nuclei are stained purple, and are counterstained with pink to observe collagen 
structure and other matrix proteins. In our previous investigation, we reported dense 
cell bands near the edge of GASD treated pericardium. We also noted moderate cell 
infiltration into the PPFSD reinforced case, as compared with the immense cell 
infiltration into the untreated pericardium case. Very densely packed cells persisting 
after 6 weeks in implantation could indicate a chronic inflammation and has 
characteristics of a foreign body response (123, 124).  
 
To further investigate this result, we stained cells for surface markers to indicate 
macrophage phenotype at or near each implant. Macrophages bare the surface marker 
CD68 regardless of phenotype, and can be classified further as M1 (CD86) and M2 
(CD206). The M1 phenotype, which is associated with host defense and pro-
inflammatory functions, is observed in higher frequency on both the UNSD and GASD 
samples than the PPFSD. M2 (CD163) phenotype, which is associated with tissue 
remodeling and constructive functions, is observed in all scaffolds, but appears to 
account for a greater portion of the total cells in the PPF reinforced samples. An M2 
weighted M2:M1 ratio can describe the host-material relationship and indicate 
remodeling. Looking closely at the representative images in Figure 4.1C, there is a 
high prevalence of the M1 stain among many macrophages in the dense cell band 
surrounding the GASD sample. We also observe high quantities of macrophages 
(identified with CD68) in the UNSD, with noticeable presence of both M1 and M2 
phenotypes. The PPFSD reinforced pericardium does have macrophages in the 




As previously described, some macrophage presence, even inflammatory, can be an 
important step in the vascular healing process. A carefully balanced population of M1 
and M2 could direct appropriate healing. Sustained presence after 6 weeks of the 
inflammatory phenotype M1 in the GASD and UNSD samples supports the observation 
of chronic inflammation and foreign body response at the injured site. Less cells 
involved in the PPFSD reinforced sample could mean fewer MMPs and matrix 
breakdown pathways, slowing the process of remodeling. This observation is 
supported by comparing the lack of original organization of matrix seen in the UNSD 
sample compared to the PPFSD reinforced sample (Figure 4.1B).  
 
Macrophages are expected to be important in determining the response to this tissue, 
as has been seen in other ECM-based implants. To investigate if PPF plays an active 
role in macrophage activation or polarization it was investigated independently of 
pericardium on the activation of splenocytes. Splenocytes represent a diverse 
population of leukocytes and were harvested from untreated SD rats. After 24 hours 
of culture with PPF, we see between 30 and 40% of splenocytes become activated 
macrophages, displaying the CD68 marker (Figure 4.2A). Further classification of 
that population in Figure 4.2B and quantified in Figure 4.2C shows a percentage of 
the population that is positive for both CD80 and CD163. Macrophage phenotype 
exists on a spectrum, and thus the positive staining of one surface marker is not a 
definitive indicator of phenotype. In the presence of high PPF, the population of 
activated macrophages shifts to relatively higher positive staining of all 3 markers. 





Figure 4. 2 In vitro Independent Cell Activation. Splenocytes that positively express the macrophage 
marker CD68 after culture with PPF films are quantified in the first graph (A). Total activation from 
PPF is observed to be lower than the inflammatory control LPS. From the cells positive for CD68, 
samples were then evaluated for positive staining of CD163 and CD80 (B). Splenocytes determined to 
be positive for these markers are summarized in the graph in Figure 4.2 C. The percentages shown in 
A, B, and C are taken from 20,000 events per group. HUVECs cultured with PPF degraded for 3 or 5 
days, or with the products of that degradation, were evaluated for changes to TNFα (D) and IL10 (E) 
gene expression. Standard deviation is displayed for technical triplicates from the RNA extracted from 
n=3 cell cultures. Groups that share letters are not statistically different as determined with an ANOVA 







The activation of splenocytes in response to PPF is less pronounced than activation to 
LPS, an established stimulatory molecule. This result suggests that PPF, if added in 
the concentrations tested, may act as an inert polymer, with slight differences based 
on the mass of foreign material in the cell environment.  
In addition to macrophage polarization, initial endothelial cell response could be an 
important factor determining the fate of a PPF pericardium patch implanted in the 
vasculature. In this setting, the relationship between macrophages and endothelial 
cells is reciprocal. Macrophages secrete growth factors VEGF, FGF, TGFB, and 
PDGF that act on endothelial cells to contribute to and stimulate angiogenesis and 
tissue repair. For example, endothelial cells can contribute to M1 stimulation with 
danger associated antigen TNFα, or can provide signals that promote expansion of 
M2 macrophages and MR macrophages, which inhibit the proliferation of M1 
macrophages, by upregulating IL10. 
 
HUVECs were cultured together either with PPF or with the products of hydrolytic 
degradation of the polymer, since realistically these smaller components may enter 
HUVECs and have different modes of action. Using gene expression analysis, an 
upregulation of TNFα was measured in response to both the 3 day polymer and the 3 
day degraded products. However, only the degraded products of 5 day degradation 
caused an upregulation of TNFα. The down regulation of TNFα in response to 5 day 
degraded films is especially interesting, since some TNFα can be expected when any 
foreign environment is encountered. The results from IL10 gene expression show a 




degradation products do not stimulate this cytokine. Independently, PPF does not 
appear to induce major macrophage or endothelial cell changes. We therefore 
conclude that changes observed in Figure 4.1 are the result of various exposures of 
the pericardium to the host.  
 
Based on the significant macrophage activation in both the subdermal study and the 
in vitro analysis, the final study was conducted in athymic rats, to isolate the role of 
the innate immune system. This final study compares pericardium with either PPF on 
both sides of the tissue (2PPFAT), pericardium with PPF on one side (PPFAT), and 
pericardium untreated (UNAT) as a control. This design controls the degree to which 
pericardium is exposed to the host. The first observation, shown with an H&E stain in 
Figure 4.3A, is the overall number of macrophages and other cells is lower in the 
athymic implants than in the SD implants. In immunocompetent systems, NK cells, T 
cells and DCs all interact with macrophage cells to suppress or propagate the 
inflammatory response (125). The lack of T cells in athymic rats could substantially 
decrease the propagation of the immune signals in response to the implant. Looking at 
the cell infiltration in H&E staining (Figure 4.3A), a distinct, one-sided infiltration of 
cells into the 1PPFAT. However, this density is only slightly less than a single side of 
the untreated control. This similarity could indicate the overall lowered amount of 
signals that recruit cells, as it is markedly different from the PPFSD and UNSD There 
are the least number of cells in the 2PPFAT. Immunohistochemical staining was used 
to identify the cell population further. The 2PPFAT has the least amount of positive 




4.3B. There is distinct CD206 stain in both the 2PPFAT and 1PPFAT, and less so in 
the untreated pericardium. At this late, 6 week time point, this could indicate a pro-
healing shift of macrophages in both the PPF reinforced cases.  
In the graph in Figure 4.3C, TNFα is quantified from homogenized samples of the 
implants at the 6 week time point. The sample 2PPFAT has significantly less TNFα 
than the UNAT sample. The PPFAT sample TNFα concentration is also less than UNAT, 
but greater than 2PPFAT. This result suggests that with increased PPF, less ECM is 
presented to the host, resulting in less TNFα. Although TNFα is a relevant molecule 
in tissue regrowth, high levels at this stage (6 weeks), can recruit and stimulate more 
M1 macrophages, leading to over production of matrix, proliferation of fibroblasts, 





Figure 4. 3 Subcutaneous Implants in Athymic Rats. After 6 weeks of implantation, scaffolds are 
explanted and stained with H&E (A), showing minimal cell infiltration (nuclei are purple) and matrix 
changes compared to the scaffolds in Figure 4.1. Using immunohistochemical staining, cells near the 
scaffold were identified as macrophages using CD68, and further characterized using CD86 (an M1 
marker) and CD206 (an M2 marker). Additionally, the scaffolds and surrounding tissue were 
homogenized and analyzed using an ELISA for TNFα (n=5 samples per group). Groups that share 
letters are not statistically different, ANOVA test & post hoc Tukey’s test (p<0.05). Scale bar is 20 μm, 





To continue to explore this relationship, more analysis should be conducted in 
immunocompetent systems. There are other cell types that are relevant to host-
material interactions that are not considered in this study including the innate immune 
system as indicated by the difference in macrophage presence between athymic and 
SD rats (112). Never the less, the results from this study indicate that PPF presence 
does not increase inflammatory metrics significantly in vivo, and in fact may reduce 
the propagation of inflammatory pathways resulting from a substantial amount of 
natural and degradable material. Increasing the presentation of pericardium and 
therefore recognizable cues as the scaffolds move from low polymer ratio to high 
polymer ratio and finally reach untreated pericardium, the expected result is that cell 
infiltration and resulting matrix remodeling should increase. This relationship can be 
leveraged to direct the appropriate timing, governed by the relationship of 







Chapter 5:  Controlled Delivery of Tissue Inductive 
Factors in a Cardiovascular Hybrid Biomaterial Scaffold3 
5.1 Introduction  
Rebuilding and maintenance of an implantable tissue construct is an essential 
consideration in designing materials for vascular grafts. Maintenance of the implant 
relies on controlled cell infiltration and production of new extracellular matrix 
(ECM), which is in part governed by the initial immune response. One method to 
initiate this process is to start with a biologically relevant material, such as native 
ECM.  Implantable devices that incorporate natural ECM often result in constructive 
tissue remodeling and minimal fibrosis (68, 70), with reduced inflammation and 
favorable macrophage polarization around the implant (29, 40, 72, 126). This result 
has been linked to providing bioactive peptide fragments as the materials degrade, 
which contribute to the recruitment of endogenous stem and progenitor cells to the 
site for ECM remodeling, and ultimately guide the invading macrophages toward a 
remodeling phenotype and attenuate the proinflammatory phenotype (55, 89, 126). 
By controlling the initial cues provided by the material design, we can influence 
cellular signaling pathways, immune response and long term fate of the vascular graft 
or implant. A material engineered to replace vessels, as complex, compliant tissues, 
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would strive to both mimic the native mechanical properties as well as encourage 
native regrowth, remodeling and maintenance of the tissue site as fast as possible.  
Hybrid biomaterials offer a platform to pursue these two goals in parallel, by 
providing initial mechanical support from a synthetic biomaterial, and including a 
viable, bioactive substrate to support native cell infiltration and remodeling. Hybrid 
biomaterials designed to mimic compliant tissue such as vessels, skin, and tendons 
have been successfully developed using a layering approach, where a distinct 
synthetic polymer component is bound to a layer of a biological material to create one 
composite material. Fabricating a material in this way can incorporate whole, 
decellularized tissue, which allows for the inclusion of many (including some 
unidentified) proteins and minerals. In several examples of biohybrid materials, the 
presence of ECM components was shown to influence the initial response of the 
immune system to promote healing, despite the polymer components that would be 
expected to individually illicit an inflammatory response (58, 64, 72). 
 
As described, cell behavior in response to the implant ultimately determines the fate 
of the injured site. In the specific cardiovascular space, studies have shown that an 
immediate development of a pure endothelial layer can significantly reduce occlusion 
of vascular grafts (127). Polymers can be selected to encourage the growth of site-
specific cells (49), but a layered biohybrid technique also provides a platform to 
further influence the local environment and control cellular response. For example, 
delivering vascular endothelial growth factor (VEGF) to sites of vascular injury has 




(128, 129). In this chapter, we describe the development of a vascular graft platform 
that can be utilized for further control through local delivery of growth factors to 
enhance cell infiltration, migration and matrix production. This system is built using 
three layers: The bottom layer consists of an ECM biomaterial which provides cell 
attachment points and biological cues. The top layer consists of a biodegradable 
polymer which can retain strength in the composite as the bottom layer is remodeled. 
The middle layer consists of quickly degrading polymer microspheres embedded 
within the slower degrading polymer used in the top layer. These microspheres can be 
utilized in the delivery of critical growth factors such as VEGF and transforming 
growth factor-beta 3 (TGFβ3) to cardiovascular tissue engineering sites.  
 
The goal of this work was to develop a directional delivery system for bioactive 
molecules that can be coupled with a hybrid biomaterial. In this chapter, we have 
designed this structure using bovine pericardium as the natural biomaterial, 
poly(propylene fumarate) (PPF) as the slower degrading polymer, and poly(lactic-co-
glycolic acid) (PLGA) for the faster degrading microspheres. 
 
The biocompatible and biodegradable polymer, PPF, was originally selected to blend 
with pericardium for the strength the polymer would lend through remodeling, as 
seen in other biomedical applications (105, 107, 130). PPF is an unsaturated, linear 
polyester that is crosslinkable through UV radiation with itself or with other 
compatible crosslinkers through the double bonds in fumarate (108).  It is 




byproducts fumaric acid and propylene glycol upon degradation (131). The 
degradation time is largely dependent on polymer characteristics such as molecular 
weight, crosslinker and crosslinking density (132). The uncrosslinked polymer is 
viscous at room temperature, allowing it to be easily “painted” onto a surface.  In 
addition, PPF viscosity can be reduced, without significantly altering the components 
of the system, with the addition of diethyl fumarate (DEF), the monomer from which 
PPF is synthesized.  The addition of DEF to PPF can also cause variations in the 
crosslinked biomaterial’s mechanical strength, and can be utilized as a parameter to 
tune the characteristics of the hybrid biomaterial (133). 
 
We have shown in Chapter 3 that a composite of PPF and pericardium demonstrates 
not only reduced macrophage infiltration and calcium deposition compared to 
chemically crosslinked vascular material alternatives, but that this composite also 
maintains the mechanical integrity and supports cell infiltration through degradation 
(63). In particular, when challenged with enzymatic degradation, the composite PPF 
pericardium material was not statistically different from GA crosslinked pericardium 
(typically used surgical material) in either elastic modulus or yield strength (Figure 
3.2) (63). Furthermore, drug delivery from PLGA microparticles coupled with PPF 
(134) as well as other polymers (135, 136) has been successfully used in previous 
research. The system described herein includes a layer of PPF with embedded PLGA 





In this current development, it was hypothesized that by using PPF as a scaffold to 
encapsulate PLGA microparticles as well as the top, slower degrading layer, a tunable 
and directional release can be achieved from the intact scaffold into the bioactive 
substrate. Release will occur as PLGA microparticles degrade hydrolytically into 
biocompatible molecules, leaving the PPF scaffold unchanged within the release time 
frame and able to support the pericardium substrate through remodeling. This chapter 
examines this platform through three objectives. First, the mechanical properties of 
the composite material, as well as the release of proteins as the polymer components 
degrade were assessed. Next, the bioactivity of encapsulated cargo was confirmed, to 
ensure that molecules are not altered in the encapsulation or release process. Finally, 








Figure 5. 1 A Schematic Of The Biohybrid Material consisting of three layers shown in the 
illustration (A), and corresponding bright field images (B) from histological samples. In C, scanning 
electron microscopy shows the two polymer layers, and the surface from which pericardium was 






5.2.1 Preparation of the Microspheres 
Microparticles were produced using a double emulsion technique by first dissolving 
100 mg of PLGA (Polysciences 50:50, Mw 150,000) in 1 mL of dichloromethane 
(DCM).  The encapsulated protein or growth factor was dissolved in phosphate 
buffered saline (PBS), and 200µL of this aqueous phase was emulsified in the 
PLGA/DCM solution using high speed vortexing. The homogeneous 
PLGA/DCM/protein solution was then poured into 3 mL of 1% polyvinyl alcohol 
(PVA) with constant vortexing, followed by alternating vortexing and ultrasonication 
for approximately five minutes.  This solution was then poured into 50 mL of stirring 
1% PVA. The solution was left stirring for four hours, after which the PVA was 
removed and the remaining microparticles were washed with deionized water and 
centrifuged at 1000 x g for 10 minutes. This process was repeated twice, and the 
spheres were then lyophilized and stored at 4°C.  
5.2.2 Polymer Synthesis and Composite Film Assembly 
PPF was synthesized by a two-step process as previously described and initiated 
using phenylbis (2,4,6-trimethylbenzoyl)-phosphine oxide (BAPO) to create a UV 
light sensitive reaction (108, 109). Lyophilized PLGA microparticles were then 
mixed with the PPF solution with mass ratios of 1:20, 1:4, and 1:2 (PPF:PLGA).  
This mixture was then placed between square, glass microscope cover slips and 
compressed to a uniform thickness of 200 µm.  The films were exposed to UV light 
(3.5 mW/cm
2




The films were embedded in paraffin and sliced into 5 μm sections for optical 
microscopy imaging (Figure 5.4 C). Image analysis measurements were taken to 
determine the relative volume ratios of each polymer component in the composite 
thin film. ImageJ (U. S. National Institutes of Health, Bethesda, Maryland) was used 
to create a binary mask in order to differentiate PLGA from PPF. Relative volumes 
were then calculated based on pixel quantity.  
 
Upon visualization of the polymer/microparticle composites (Figure 5.4 C), the 1:2 
PLGA:PPF mass ratio presented the most tightly packed microsphere organization 
among the visualized ratios. It was anticipated that degradation of the microspheres in 
this composite would allow for the most extensive interconnected network compared 
with the other investigated ratios. As such, the 1:2 PLGA:PPF mass ratio was 
ultimately selected for additional evaluation within this study. The 1:2 mass ratio 
yields a PLGA:PPF volume ratio of 1:1.01 and approximately 50 mg of 
microparticles per film. 
5.2.3 Degradation Assessment  
To assess PLGA particle degradation, microspheres were manufactured as described, 
using either PBS or a 200 mg/mL solution of ovalbumin (OVA) as a representative 
antigen in the aqueous phase. Samples of PLGA microspheres were placed in PBS 
solution (4 mg/5 mL) and incubated at 37°C while shaking for 21 days. At 
predetermined time points 3 groups of 4 mg of spheres from each set were stopped 
and lyophilized. After 21 days, all groups were analyzed using a gel permeation 




(Mn) of PLGA. A Student’s t-test was conducted to assess statistical difference 
between unloaded and loaded microspheres at each time point.  
 
Mass loss was used to assess PPF film degradation independently from PLGA, since 
the crosslinked products are not suitable for GPC analysis. Films of PPF were created 
by crosslinking the polymer in between 2 glass coverslips as previously described in 
Chapter 2. The films were cut into quarters and massed, and incubated in PBS at 
37°C while shaking.  At predetermined time points, six films were oven dried for 24 
hours before measuring final mass. Mass loss was calculated following:  
 𝑇ℎ𝑖𝑛 𝐹𝑖𝑙𝑚 𝑀𝑎𝑠𝑠 𝐿𝑜𝑠𝑠 =  
𝑀𝑎𝑠𝑠 𝑎𝑓𝑡𝑒𝑟 𝑐𝑟𝑜𝑠𝑠𝑙𝑖𝑛𝑘𝑖𝑛𝑔−𝑀𝑎𝑠𝑠 𝑎𝑓𝑡𝑒𝑟 𝑑𝑒𝑔𝑟𝑎𝑑𝑎𝑡𝑖𝑜𝑛
𝑀𝑎𝑠𝑠 𝑎𝑓𝑡𝑒𝑟 𝑐𝑟𝑜𝑠𝑠𝑙𝑖𝑛𝑘𝑖𝑛𝑔
.  
5.2.4 Release from Films and Free Microspheres  
Two individual studies were performed in order to measure the rate at which OVA 
molecules would be released from freestanding microparticles in an aqueous 
environment, and from microparticles embedded within a PPF thin film.  
Microparticles in solution were prepared in 25 mg samples, and incubated at 1 
mg/mL, shaking at 37°C.  At each predetermined time interval, 200 µL of solution 
was removed from the vial and flash frozen for later analysis.  200 µL of PBS was 
replaced in each vial in order to maintain constant volume.  This same procedure was 
repeated for composite films, where one film is immersed in 25 mL of PBS.  After the 
collection of samples from all time points, the extracted PBS was analyzed using a 




5.2.5 Construction and Assessment of Hybrid Material 
Although the composite of pericardium and PPF has been previously described, the 
incorporation of the PLGA microparticles could alter relevant mechanical 
characteristics, namely the elastic modulus of the composite and the adhesion 
between the PPF layer and the pericardium. Samples of pericardium coated with PPF 
with and without PLGA microparticles, and then crosslinked using UV light (63). All 
samples were then rehydrated in PBS. Using a universal testing machine (Model 
1185, Instron, USA) eight samples were subjected to tensile testing, with a set 
extension rate of 10 mm/min. Extension and corresponding load was recorded at a 
frequency of 10 Hz, and a preload of 5 N was applied. The elastic modulus and 0.1% 
yield strength for each sample was calculated using MATLAB to determine the slope 
of the linear region of the stress–strain curve reported by the Instron software. A 
Student’s t-test was conducted to assess the significance between PPF with and 
without the PLGA.  
 
To test adhesion, following an adaptation from ASTM standard D5868, samples of 
pericardium were prepared through the described dehydration method before coating 
in either PPF or the PPF+PLGA microsphere composite (63). Poly(propylene) mesh 
of equivalent size to the pericardium was gently pressed into the liquid phase of the 
polymer (Figure 5.2). The pericardium/mesh/PPF sample was then crosslinked with 
UV light, allowing the PPF polymer to solidify and crosslink with itself around the 
mesh. This creates a “tab” that is physically integrated with the polymer layer, and 





Figure 5. 2 Adhesion Testing Schematic This schematic demonstrates the approach to test adhesion 
between the polymer layer and the pericardium substrate. Briefly, samples of pericardium were coated 
in either PPF or the PPF+PLGA microsphere composite. A poly(propylene) mesh of equivalent size to 
the pericardium was gently pressed into the liquid phase of the PPF top layer. This mesh served as a 
“tab” to pull the polymer layer the opposite direction as the pericardium, and causing the polymer layer 





during the testing. The whole material was then rehydrated overnight in PBS. Each 
sample was pulled to failure, by pulling the mesh tab and the pericardium in parallel 
but opposite directions, on an Instron testing frame, at an extension speed of 10 
mm/min, with a sample size of eight per group. Failure is defined when the PPF has 
separated from the pericardium. Again, a Student’s t-test was conducted to assess the 
difference in adhesion between PPF with and without the PLGA. 
5.2.6 Demonstration of Effect on Cells In vitro 
Release of bioactive factors was first investigated using PLGA microparticles with 
encapsulated TGFβ3 as a large representative bioactive molecule. These PLGA 
microparticles were made as previously described, by incorporating 100 ng/mL of 
recombinant human TGFβ3 (R&D Systems, Minneapolis, MN) into the aqueous 
phase of particle manufacture. The microparticles were embedded within PPF thin 
films, and crosslinked with UV light. The composite thin films were then added to 
human umbilical vein endothelial cell (HUVEC) culture. Over five days, media 
samples were collected from cell cultures containing the composite thin films and 
tested for TGFβ3 concentration using an enzyme-linked immunosorbent assay 
(ELISA). These samples were compared to media samples from cell culture 
supplemented with soluble TGFβ3, cell culture with blank PPF films, and unaltered 
cells as control groups. Within each time point, a one-way ANOVA was conducted to 
compare the TGFβ3 concentration between the samples, followed with a post hoc 





Delivery of bioactive factors to cells was next assessed through two established 
bioassays. To confirm that the release of the factor from the composite thin film 
evoked changes in cell behavior, both a proliferative (VEGF to HUVECs) and a 
cytotoxic molecule (tumor necrosis factor-alpha (TNFα) to the NCTC clone 929 [L 
cell, L-929, derivative of Strain L] (ATCC® CCL-1™) (L929)) were released 
separately, and compared to control cultures with blank PLGA microspheres, both 
free and embedded in PPF, as well as to pure PPF thin films. 
 
PLGA microspheres were manufactured as previously described. Into the initial 
aqueous phase, either 40 ng of human recombinant VEGF165 (Sigma-Aldrich, St. 
Louis, MO), or 50 ng/mL of recombinant human TNFα (R&D Systems, Minneapolis, 
MN ) were incorporated per mg of PLGA. Resulting PLGA microspheres were 
embedded within PPF thin films.  
 
The following assays were carried out using these bioactive films. First, in agreement 
with previously published results (137, 138), human TNFα composite films were 
added to L929 cell culture (corresponding to 4 mg of PLGA microspheres, or 6.5 
ng/mL of TNFα culture media). Cells were sensitized using actinomysin-D (4 
µg/mL), and metabolic activity was evaluated after 24 hours using an XTT assay. 
Adequate doses of TNFα are reported to cause apoptotic cell death in L929s when 
sensitized with actinomysin-D. A dose dependent response of L929s to soluble TNFα 
was also confirmed with the XTT metabolic assay (Figure 5.3). Absorbance readings 




considered to be at 100% metabolic activity. In parallel, VEGF containing films were 
added to culture of HUVECs (corresponding to 4 mg of PLGA microspheres, or 60 
ng/mL culture media). After 72 hours, HUVECs were evaluated using the XTT 
metabolic assay. Results from each assay where compared to each other using a one-
way ANOVA with a post hoc Tukey’s test.  
 
Results from these studies were confirmed with fluorescent stains, both Live/Dead 
and immunohistochemical staining. In the Live/Dead stain, cells are washed with 
PBS, and then incubated for 45 min with a solution of 4 µM of calcein AM 
(Invitrogen, Carlsbad, CA) and 2 µM of ethidium homodimer (Invitrogen, Carlsbad, 
CA).  For immunohistochemistry, cells were fixed in 4% para-formaldehyde, 
permeabilized, and blocked following recommendations for the primary antibodies. 
Cells were stained using the following antibody set and stains: an anti-Collagen I 
antibody (ab21286, 1:200) followed by a goat anti-rabbit fluorescein isothiocyanate 
(FITC) conjugated secondary antibody (1:200), an actin stain Alexa Fluor® 594 
Phalloidin (2.5%), and a cell nucleus stain VectaSheild® plus 4',6-diamidino-2-






Figure 5. 3 Dose Response for Established Bioassayss. Data from XTT analysis confirming the 
expected result to metabolic activity when various concentrations of TNFα are added to the culture 





5.2.7 Demonstration of Directional Release 
PLGA microspheres with OVA encapsulation were used in this experiment. 
Pericardium/PPF/PLGA composite samples as well as PPF/pericardium samples were 
individually submerged in 20 mL of PBS and incubated while shaking at 37°C. At 
time points of 0, 1, 3, 5, and 7 days, samples from both groups were removed from 
the study, fixed in 4% paraformaldehyde, and embedded in paraffin for histological 
examination. PBS solution containing the sample was tested using a Bradford assay 
for available OVA concentration in the solution.  
 
OVA presence in the pericardium tissue resulting from directed release from 
PPF/PLGA composite was investigated using immunohistochemistry. Slices of the 
composite (5 µm) were incubated with BackgroundSNIPER1 (Biocare), a broad 
spectrum blocking reagent, and then incubated with anti-OVA primary antibody 
(rabbit polyclonal to OVA, Abcam ab74384, 1:500). This antibody was detected with 
a biotinylated anti-rabbit IgG (Vector Laboratories, 1:200), and an 
aminomethylcoumarin (AMCA) conjugated streptavidin (1:200). Fluorescent images 
were merged with phase contrast images of the construct.  
5.3 Results and Discussion 
The first objective of this study was to confirm that the mechanical properties of the 
composite material, specifically elastic modulus, yield strength, and adhesion 
between the layers, are suitable for use as a graft in the cardiovascular space. 
Typically, human vessels are reported to have an elastic modulus between 4-12 MPa 




(96, 97, 139-141). Materials used as grafts are reported to have elastic moduli 
between 5-30 MPa with ultimate tensile strength of 2-10 MPa (54, 63, 98, 142-144), 
placing these previously developed materials in the same range as the native vessel. It 
is important to match characteristics such as mechanical strength and compliance 
with the native tissue, as pointed out in a recent review, since poorly matched 
mechanical properties can affect remodeling of the site, blood flow dynamics, and 
cause issues such as bursting or fraying at the sutures (145). Evaluation of the elastic 
modulus and 0.1% yield strength of our composite material show that the inclusion of 
PLGA microparticles does not significantly alter the modulus and yield strength of 
the composite when crosslinked in a thin film, as shown with a Student’s t-test 
(p>0.05) (Figure 5.4 D). Elastic modulus in particular was found to be between 40 
and 65 MPa for these materials, both placing it at the high end of the range of moduli 
from previous engineered vascular graft material, and aligning it with reported values 
of GA treated pericardium (the surgical gold standard for vascular repair) (63). 
Furthermore, the adhesion between the PPF and the pericardium layer again are not 
significantly altered when PLGA microparticles are included in the material 
(Student’s t-test (p>0.05)). In this assessment, both combinations (PPF/pericardium 
and PPF/PLGA/pericardium) were found to remain adhered until 0.05 MPa of stress. 
These results suggest that the layered biohybrid material is still within a suitable 
range for compliant tissue approximation, and will resist delamination at a similar 
strength to other adhesive surgical glues. In Chapter 2, we found the modulus of 




pericardium/PPF/PLGA material within an appropriate range to interact with the 






Figure 5. 4 Characterization of the Composite Polymer Layer. In A, degradation of PLGA 
microparticles with and without OVA encapsulated (loaded vs unloaded) as measured with GPC shows 
significant loss of molecular weight (Mn) over 20 days (n=3 per time point). This degradation is much 




(n=6 per time point). C shows bright field images of composite thin films with mass concentrations of 
PLGA microparticles embedded within them. D shows mechanical analysis of the composite thin 
films, including elastic modulus, 0.1% yield strength, and the maximum shear stress that can be 
applied to the biohybrid material before the composite polymer layer separates (n=5 per group). A 
Student’s t-test shows no significant difference between PPF with or without PLGA. Figure 5.4 E 
shows the release of OVA from PLGA microparticles contained within the PPF film (composite films) 





Within this first objective to characterize the composite material, the expected release 
of proteins as the polymer components degrade was also assessed. The microparticle 
fabrication resulted in spherical particles with a mean diameter of 25 ± 11 µm, which 
was measured using light microscopy. The degradation of the PLGA microparticles 
over 21 days is shown in Figure 5.4 A, as decreasing molecular weight from the 
starting number average molecular weight of 70,000 Da to an average of 20,000 Da 
by day 21. The average molecular weights between OVA loaded and blank 
microparticles do not differ statistically, as shown by a Student’s t-test (p>0.05) 
within each time point. The degradation of PPF thin films is also shown in Figure 5.4 
B, represented by retained mass % over 500 days. The degradation of PLGA is much 
faster than PPF, which confirms that the PLGA microparticles will be able to degrade 
into solution and release bioactive molecules while the PPF remains.  The lasting PPF 
construct retains strength and structure in order to hold PLGA microparticles in place 
while they completely degrade, as well as to maintain adherence to the pericardium 
substrate.  
 
The release of OVA from microparticles both free in solution and from within thin 
films is shown in Figure 5.4 E. The amount of protein is normalized to the mass of 
PLGA microparticles tested in each experiment. The release of OVA from 
microparticles shows a constant initial release of protein until day three, at which 
point the rate of release slows and the concentration of protein in solution remains 
constant. This constant concentration is indicative of the maximal protein release 




release during the first three days, and then the concentration in solution remains 
constant. The initial release from composite thin films was recorded at lower 
concentrations than that of microparticles alone.  This difference is expected due to 
the reduced surface area of microparticles that are exposed to the solution. The 
timeline of release observed is in line with other studies that suggest a quick influence 
of growth factors like VEGF (on the order of days) can affect vascular remodeling 
and influence the early formation of an endothelial layer, contributing to success of 
the graft (146-148).  
 
In objective two, the bioactivity of encapsulated cargo was confirmed, to ensure that 
molecules are not altered in the encapsulation or release process. From the composite 
thin film, we confirmed that three possible bioactive factors retained functionality 
through the embedding and release process. First, TGFβ3 concentration was 
measured in cell cultures with the composite thin films loaded with TGFβ3. This was 
compared to cultures supplemented with TGFβ3 and from cultures containing blank 
polymer microspheres and films. Results first show a matching concentration 
between what was measured with the ELISA to the amount added into culture media 







Figure 5. 5 Release of Active Growth Factors from Composite Films. TGFβ is released into cell 
culture from composite films (A) and supplemented into culture (B); the data are separated into panels 
(A) and (B) due to the significant differences in the ordinate’s scale. TGFβ released from composite 
films shows sustained presence in cell culture over 5 days that is significantly higher than both blank 




groups (B) after the media change between day 1 and day 2. This was confirmed using a one way 
ANOVA and post hoc Tukey’s test to compare groups within the same time point from both panel (A) 
and panel (B). Groups that do not share a letter in this graph are significantly different (p<0.05). Figure 
5.5 C shows fluorescently stained cell cultures after delivery of either TNFα, which is seen to kill 
L929s, or VEGF, which increases collagen and actin staining in HUVECS. The scale bar represents 20 
μm. Figure D corroborates this result with metabolic activity assay of the tested cell cultures (n=3). 
Groups that do not share a letter are significantly different (p<0.05) as determined with a one way 





Concentration of TGFβ3 in cultures with the composite thin films maintained a 
moderate level throughout the study, even after the media change, indicating a 
constant release of the molecule from the composite thin films. The TGFβ 
concentration dips slightly after the media change between day one and day two, but 
composite films continue to release and sustain the concentration, creating a 
significantly higher concentration than the supplemented media samples, as 
determined with a one-way ANOVA and post hoc Tukey’s test (p<0.05). The ability 
of the ELISA to accurately bind and measure concentration of the molecule suggests 
the molecule retains at least a portion of its original physical conformation, meaning 
it is unaltered by the encapsulation or release processes. Maintenance of the 
molecule’s physical conformation suggests that the molecule may retain biological 
activity, although this result for TGFβ3 is untested.  
 
We continued to investigate the retained activity of encapsulated bioactive factors by 
performing two established bioassays. To confirm that the released factor and not the 
polymer carriers is responsible for changes cellular behavior, both a proliferative 
(VEGF to HUVECs) and a cytotoxic molecule (TNFα to L929s) were selected for 
investigation. Delivering TNFα to L929 cells through a composite thin film resulted 
in significantly reduced metabolic activity of the cells when compared to cells in 
culture with blank microparticles, blank microparticles in films, and plain films 
(Figure 5.5 D), as determined with a one-way ANOVA and post hoc Tukey’s test 
between all groups. This result indicates that TNFα is successfully released from the 




were independently confirmed by directly adding TNFα to L929 culture, and 
assessing metabolic activity (Figure 5.3). The effect of the TNFα composite films on 
L929s is visually confirmed with the Live/Dead stain (Figure 5.5 C). In Figure 5.5 C, 
L929s with TNFα composite thin films have reduced population and viability, 
indicated by the presence of the red stain within the cell membrane. On the other 
hand, HUVECs in culture with composite films with VEGF show improved 
metabolic activity when compared to cells in culture with blank microparticles, blank 
microparticles in films, and plain films (Figure 5.5 C). This result supports VEGF is 
successfully released from the composite in an active form, capable of inducing 
proliferation or matrix production in HUVECs. The effect of the composite films on 
HUVECs can be seen in the immunofluorescent images in Figure 5.5 C, where 
HUVECs with the composite film appear to have increased density, as well as 
increased collagen and actin staining compared with the control groups of cells. Both 
sets of results are consistent with metabolic activity data assessing the effect of 
soluble factor delivery to cells, which are presented in Figure 5.3A and 5.3B. We 
have also confirmed the viability of L929 cells in culture with the materials for 2 






Figure 5. 6 Composite Polymers Effect on Viability. Confirmed viability of L929 cells in culture 
with the PPF/PLGA composite material for 2 points over 48 hours. Data is presented normalized to the 








Figure 5. 7 Directional Delivery from Composite Layer into Pericardium Substrate. Pericardium 
tissue samples coupled with OVA-loaded composite films PLGA/PPF or with just PPF layers were 
immunostained using an antibody for OVA, indicated with a localized blue stain. Staining shows OVA 
contained primarily in the polymer layer on day 0, moving into the pericardium tissue by day 5. There 
is very low blue fluorescence observed in the PPF and pericardium samples, corresponding to the 







In the third objective, the location of released proteins is confirmed in an in vitro 
analysis of the complete biohybrid material. Directional release of OVA into the 
pericardium substrate is demonstrated in Figure 5.7. A Bradford assay confirms no 
detectable free OVA in solution in either sample group. However, the histological 
stains confirm its presence in and around the pericardium layer when delivered with 
the PLGA/PPF layer of the hybrid. As shown in Figure 5.7, on day 0, before 
significant hydrolytic degradation has occurred, the OVA stain (blue) is primarily in 
the PLGA/PPF layer of the construct. By day three, some OVA staining is observed 
in the tissue, and increases by day five.  
 
By using PPF as a scaffold to encapsulate PLGA microparticles, a tunable and 
directional release of bioactive molecules can be achieved. As PLGA microparticles 
degrade hydrolytically into biocompatible molecules, the encapsulated cargo is 
released and appears to move freely into the space created by degrading surrounding 
PLGA particles. In this design, that space preferentially sends the bioactive molecules 
into the pericardium or biomaterial substrate, and exposes the next plane of 
microspheres for hydrolytic degradation. In addition to the directional release, this 
design can also be used to achieve either a sequential or simultaneous delivery of 
multiple growth factors, by creating separate populations of microsphere carriers. 
Other studies have suggested that delivery of platelet-derived growth factor (149), 
hepatocyte growth factor (150), brain-derived neurotrophic factor (146) or stromal 
cell-derived factor-1(151) in addition to VEGF could be beneficial in vascular 




The much slower degrading interconnected PPF network will initially remain intact 
as a strong and durable material, but eventually degrades into biocompatible 
molecules as well. During the remodeling process, the PPF support layer can provide 
critical mechanical support without causing detrimental side effects such as 
calcification and fibrosis formation, as demonstrated in previous in vivo studies in 
Chapter 2 and elsewhere (63, 142). In selecting spheres as the vehicle for delivery, we 
allow the PPF support layer to fill in the spaces between PLGA spheres, therefore 
ensuring the bulk polymer PPF is adhered to the pericardium substrate in this 
intermediate layer. This maintains the support relationship as the PLGA microspheres 
degrade.  
 
Recent studies have reported on hybrid biomaterial systems that have been fabricated, 
by layering a polymer scaffold with a natural, decellularized matrix-type material for 
applications in skin (50), cardiac and vascular tissue (30, 53), and abdominal muscle 
injury(58). This paper serves to advance the technologies used in these systems as it 
describes a way to build ECM-based biohybrid material that promotes controlled 
regrowth of the injured site by not only the intrinsic material properties, but also by 
delivering growth factors and cytokines that can enhance the remodeling process.  
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Chapter 6: 3D Printed Pericardium Hydrogels Promote 
Wound Healing Response in Vascular Tissue Scaffolds 
 
6.1 Introduction  
Scaffolds that incorporate molecules from the extracellular matrix (ECM) of the 
target tissue create a bioactive platform upon implantation that can positively 
influence natural tissue regeneration. Incorporation of these molecules, such as 
proteins and growth factors, is aimed at mimicking one or more of the responsibilities 
of the ECM. Constituents of the ECM provide cues for diverse functions such as cell 
signaling pathways (152), shape and function (153), proliferation and migration (154-
156), and cell differentiation (157, 158). Due to broad application, complexity, and 
tissue specificity of ECM, it is unlikely that a manmade or natural material can 
recapitulate all the features of the ECM. Evidence is emerging that simply 
incorporating predetermined building blocks into a tissue engineering scaffold may 
over simplify the environment, and ignore critical structures, binding sites, and 
signals critical to development at the implant site.  
 
Scaffolds that instead use tissue derived and site specific ECM have been shown to 
significantly enhance cell recruitment, support remodeling of the scaffold, and 
modulate the immune response to enhance healing of the injured site over single or 
controlled component scaffolds (21, 114, 159). This mechanism is thought to be a 




scaffold (160, 161), unique combinations of fibrous proteins like collagen, fibronectin 
and laminin that support host cell attachment (113), or peptides that modulate the 
phenotype of arriving macrophages (162).  
 
Modulation of the immune response by these scaffolds is especially relevant in 
vascular tissue engineering. When scaffolds are implanted, macrophages are among 
the first responders (124, 125). Upon arrival and differentiation, macrophages can 
initiate and contribute to wound healing and/or inflammatory pathways that can 
support or exacerbate the healing process. Beginning with acute inflammatory 
response to injured endothelial and smooth muscle cells near the implant site, 
macrophages will phagocytose wound debris, secrete enzymes that work towards 
tissue reorganization, and produce cytokines and growth factors that cause migration 
and proliferation of fibroblasts (118) to initiate the reparative response. The dynamics 
of this process may be effected by the population of macrophages that develop and 
persist at the injured site (116, 163). If arriving macrophages adopt a healing 
phenotype, they will aid in the process of regeneration by secreting cytokines like 
vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF1), or 
transforming growth factor beta 1 (TGF-β1) that signal for matrix reorganization and 
rebuilding, especially by stimulating vessel growth (VEGF) and stabilizing 
neovessels (platelet derived growth factor) (116). However, if a majority of arriving 
cells adopt and then sustain a classically activated (M1) phenotype, inflammatory 
chemoattractants (Interleukin (IL) 1, tumor necrosis factor α (TNFα), IL 12, C-C 




the inflammation. This can result in excessive proliferation and formation of a fibrotic 
capsule (118). In vascular tissue grafts, several studies have now linked an excessive 
and sustained inflammatory response marked with macrophages (164), natural killer 
(NK) cells and C-reactive protein (165) to stenosis in as fast as 2 weeks after 
implantation (166). It is suspected that a higher and sustained density of M1 
macrophages impedes the initiation of the remodeling phase, where a more moderate 
ratio of M1:M2 phenotypes could initiate a healing response. Evidence of this process 
is observed in that the moderate infiltration of macrophages plays a role in 
regeneration and neovessel formation (166).  
 
The presence of ECM has been shown to direct the healing response toward the 
scaffold in an anti-inflammatory way, by causing a macrophage to differentiate more 
towards the M2 phenotype and a TH2 favored cytokine profile (40, 118, 123, 167, 
168). The mechanism, although not fully understood, likely involves cross talk 
between the arriving macrophages, endothelial cells, as well as other immune 
modulating cells in response to binding sites, cryptic peptides and adhered growth 
factors. The degradation of ECM scaffolding is mediated by enzymatic processes, 
which helps control the release of cryptic peptides from collagen, fibronectin and 
fibrinogen that can serve as chemoattractants for vascular specific cell types, initiate 
matrix rebuilding pathways, and modulate proliferation (115, 118, 169-171). In 
addition to, or perhaps as a result of decreased inflammatory response, ECM scaffolds 
encourage endogenous repair (113, 172) and promote cell differentiation and the 




specific ECM scaffolds have been developed by several groups. One such study 
demonstrates enhanced maturation of cardiomyocytes, cardiac progenitor cells on 
ECM scaffolds compared to collagen, gelatin, and nonspecific site ECM scaffolds 
(160, 173). Similarly, another group improved migration of rat endothelial cells, rat 
aortic smooth muscle cells, and human coronary artery cells compared to collagen 
scaffolds (172). A third report  increased endothelial cell and smooth muscle cell 
infiltration and in vivo arteriole formation in myocardial matrix ECM compared to 
non-specific ECM (21). 
 
Appropriate cell recruitment and modulation of the inflammatory response are clearly 
two important processes in vascular tissue engineering that can be achieved by using 
an ECM-based scaffold. In addition to the importance of chemical constituents, 
matrix stiffness controls numerous cell functions including durotaxis (174), focal 
adhesions, cell proliferation (175), and stem cell differentiation (176) of cells 
recruited to the injured site. Although some ECM components can re-assemble into 
robust 3D structures on their own, these hydrogels can be relatively weak compared 
to synthetic hydrogel components, and as such are not suitable as a compliant tissue 
replacement which is required in the vasculature. Several studies have indicated a 
change in endothelial cell proliferation and the formation of cell-cell networks 
depending on the modulus of the hydrogel scaffold (177, 178). Additionally, a 
compliance mismatch between the graft and the native vessel is linked to intimal 
hyperplasia of vascular grafts, indicating the importance of appropriate response to 




biohybrid material as an approach to combine the bioactivity of an ECM-based 
material with the strength and controlled degradation of a synthetic polymer.  
 
To build a biohybrid material, we present research here combining decellularized and 
homogenized bovine pericardium with polyethylene glycol (PEG) diacrylate into a 
chemically crosslinked hydrogel. Pericardium is a matrix dense tissue, composed of 
many of the same proteins and glycans as vascular tissue, including the proteins 
collagen, elastin, fibrillin, and fibronectin (172). The fiber proteins provide tensile 
strength, while other components act as cell adhesion domains for cell-matrix 
interaction (118). In particular, glycosaminoglycans (GAGs) act as a reservoir for 
growth factors and preserve their activity by protecting against enzymatic 
degradation, while also holding them to a specific location (118). Additionally, 
pericardium is sparsely cellularized, and due to the easily removed, light DNA 
content, it is an ideal candidate to donate xenographic tissue (112, 179, 180). 
Pericardium has been used extensively in graft and scaffold material (113) although it 
is primarily used in cardiovascular applications (113) due to its high collagen content, 
which gives it superb mechanical strength.  
 
PEG has been used extensively in biological scaffolds as well, and is often chosen to 
intentionally not react with the host due to the non-adhesive nature of PEG polymer 
chains (181). However, it can be modified to be included in scaffold that on the whole 
is both bioactive and biodegradable (78). In these applications, it is used primarily as 




this way does not interfere with the tissue specific composition of the ECM. PEG has 
been selected to enhance the mechanical properties of ECM hydrogels specifically in 
porcine cartilage and gelatin methacrylate (gelMA) (182), myocardial matrix (80) and 
collagen (183, 184).  
 
To increase the elastic modulus of homogenized pericardium in a way that does not 
interfere with the biochemical content, we propose to chemically react PEG with the 
proteins in homogenized pericardium matrix (HPM). The objectives of this work are 
to first derive active matrix components from pericardium, and then form a 
controllable and structurally strong hydrogel scaffold. To achieve the utmost 
architectural control, we will develop this hydrogel for a cyto-compatible printing 
method using visible light photoinitiation and digital stereolithography. With this 
scaffold, we can then direct the signs of vascular regrowth and inflammatory response 
that are induced or supported by our scaffolds using various mechanical strengths to 
effect endothelial cell growth and concentrations of ECM to effect macrophage 
polarization. Understanding the interaction between arriving macrophages, 
endothelial cells, and the designed scaffold is essential in the regeneration process for 
vascular tissue. Looking at these two cell populations in co-culture can allow us to 
experimentally measure their interaction with each other and the material scaffold. 
We hypothesize that the addition of PEG to HPM will result in an increased elastic 
modulus, and will also slow the presentation of ECM, allowing for a moderate 




6.2 Methods  
6.2.1 Tissue Homogenization  
Whole bovine pericardium was obtained fresh from Innovative Research, Inc. 
Decellularization was conducted similarly to previously established methods (172, 
185). To homogenize, the tissue was first rinsed to remove blood and excess fascia. 
Next, it was cut into 1 cm
2
 squares which were flash frozen in liquid nitrogen. Frozen 
samples were then mechanically ground into a fine powder (Krups, F203 Electric 
Grinder with Stainless Steel Blades). Pericardium powder was lyophilized to obtain 
total tissue mass. This powder was then digested at a concentration of 10 mg/mL with 
1 mg/mL of the enzyme pepsin. For digestion, the pH of this solution was adjusted to 
2 using 1M HCl. After 72 hours, the solution was neutralized to a pH of 7.4 using 1M 
NaOH, and the salt concentration adjusted by adding 10x phosphate buffered saline at 
1/9
th
 of the digest volume. The neutralized, homogenized pericardium matrix (HPM) 
was then frozen at -20 °C until time of use.  
6.2.2 HPM Characterization  
Concentrations of various protein components in the HPM were determined using the 
following assays: total protein was tested using the Bradford Assay (ThermoFisher), 
collagen concentration was determined using the hydroxyproline assay (Sigma 
Aldrich), and glycosaminoglycan (GAG) concentration was determined using the 
dimethyl-methylene blue (DMMB) assay. DNA content remaining in the HPM was 
quantified using a PicoGreen Assay. All concentrations determined were expressed as 





Samples of HPM were diluted to 1 mg/mL total protein and prepared for sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) following standard 
protocols (BioRad). Briefly, samples were mixed with 25% laemmli buffer containing 
10% β-mercaptoethanol, heated at 95 °C for 5 min, and then loaded into a 4–15% 
Mini-PROTEAN® TGX Stain-Free™ Protein Gel (BioRad). Standard human 
collagen type I (Corning, Corning NY) was also run as a control. SDS-PAGE gels 
were stained with coomassie brilliant blue for total protein bands. Protein bands were 
also transferred to nitrocellulose membranes and stained using primary antibodies for 
collagen I (Rabbit Polyclonal Collagen I alpha 1 (1:5000 dilution), fibronectin 
(Rabbit Polyclonal Fibronectin/Anastellin 1:1000 dilution) and collagen IV (Rabbit 
Polyclonal Collagen IV alpha 1, 1:1000 dilution) (Novus Biologicals). Positive 
staining was detected using IRDye® 800CW Goat anti-Rabbit IgG fluorescent 
secondary antibodies (LI-COR) on an Odyssey CLx Platform (LI-COR).  
 
For mass spectrometry and protein identification, SDS-PAGE gels were digested with 
sequencing grade Trypsin (Promega) and resulting peptides were extracted with 
Acetonitrile-Formic acid buffer. The peptide mixtures were sequentially analyzed by 
LC-MS/MS using nano-LC system (Easy nLC1000) connected to Q Exactive mass 
spectrometer (Thermo Scientific). The mass spectrometry data was collected in data-
dependent manner switching between one full scan MS mode (m/z 380-1600, 




MS/MS analysis of the top 10 target ions were performed once and dynamically 
excluded from the list for 20 seconds.  
6.2.3 PEG +HPM Hydrogel Formation  
Two forms of modified PEG were investigated: 4arm PEG Acrylate (20,000 kDa, 
JenKem Technologies USA, Plano Texas) and PEG diacrylate (5,000 kDa, Laysan 
Biologics). PEG and HPM hydrogels were formed using the visible light 
photopolymerization method described by Bahney et al (186). In this reaction, eosin-
Y acts as a photosensitizer, excited at a wavelength of 510 nm. Activated eosin-Y can 
then deprotonate triethanolamine (TEA), which in the presence of n-vinylpyrrolidone 
(NVP) can initiate crosslinking between the acrylates and the free amines in the ECM 
proteins. The following concentrations of initiators were investigated in this study:  
Table 6.1 Photoinitiator Concentrations 
Reagent Concentration 




To create 3 dimensional scaffolds, shapes were first designed using SolidWorks® 
(Waltham, MA). Scaffolds were then fabricated using an EnvisionTEC Perfactory® 
P4 (EnvisionTEC, Detroit, MI). Using digital stereolithography, the liquid resin 
(containing PEG, ±HPM, and photoinitiators) was crosslinked with an exposure of 
800 mW/dm
2
 for 240 seconds per 100 µm step size. Optimal combination of reagents 
were selected to minimize time to crosslink among samples that supported at least 




6.2.4 Evaluation of PEG+HPM hydrogels 
Hydrogels were formed as described above using 5% PEGda, 1% HPM, 0.5% TEA, 
10 μM EOSIN and 37 mM NVP. Concentration of free amines were quantified in pre 
and post-crosslinked materials and solutions using a TNBSA assay (Sigma) to 
confirm the reaction had taken place. In addition, pre and post crosslinked materials 
were examined using Fourier transform infrared spectroscopy (FTIR). FTIR 
measurements were acquired using a Smiths IlluminatIR II with samples mounted on 
MirrIR Low-e Microscope Slides (Kevley Technologies). 128 scans per sample were 
taken under ATR mode, imaging a 100 um^2 area, with background computed and 
removed for each measurement. Samples (n=6 per test set) were run per conditioned 
and the average absorbance vs. wavenumber (cm-1) was computed. 
 
Biodegradation was compared between PEG hydrogels without HPM (referred to as 
PEG (-) ) and PEG hydrogels with 1% HPM (w/v) (referred to as PEG+HPM). For 
this test, 10 cylindrical scaffolds (diameter 7mm, height 5mm) were formed for each 
of the following compositions: 5% starPEG-acrlyate + 1% HPM, 5% starPEG-
acrlyate without 1% HPM, 5% PEGDA + 1% HPM 5% PEGDA without 1% HPM. 
All scaffolds were crosslinked with 0.5% TEA, 10 μM EOSIN and 37 mM NVP. 
Scaffolds were lyophilized to obtain starting mass. Five from each group were 
submerged in water, and the remaining 5 were submerged in 0.4 U/mL of 
collagenase. After 5 days, gels were rinsed with water and lyophilized again. 
Degradation is represented by percent mass loss using the following equation: 
% 𝑀𝑎𝑠𝑠 𝐿𝑜𝑠𝑠 = (1 −  
𝑀𝑎𝑠𝑠𝑖𝑛𝑖𝑡𝑖𝑎𝑙−𝑀𝑎𝑠𝑠𝑓𝑖𝑛𝑎𝑙
𝑀𝑎𝑠𝑠𝑖𝑛𝑡𝑖𝑎𝑙




Dynamic mechanical analysis (DMA) was conducted on a Q800 DMA (TA 
Instruments). Discs of hydrogel scaffolds were formed (diameter 7mm, height 5mm) 
using the formulations listed in Table 2. Scaffolds were first treated with a preload of 
0.01 N, and then were tested using a strain sweep with a fixed frequency (1 Hz) to 
determine the stress-strain curve and the compressive modulus. From each 
formulation, 5 scaffolds were tested, and standard deviations are reported.  
Table 6.2 Concentrations of Hybrid Hydrogels  








0% 10%  
 
6.2.5 Cell Metabolic Activity Assay 
The cell line L929 (ATCC) was cultured according to supplier instructions, and used 
for basic viability testing. Hydrogel scaffolds were formed using combinations of the 
reagents listed in Table 1, and crosslinked in 96 well plates to facilitate even and 





cultured at 37 °C for 3 days. Cell metabolic activity was quantitatively assessed using 
Cell Proliferation Kit II (Roche, Mainheim, Germany). XTT [2, 3-bis-(2-methoxy-4-
nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] was used in this assay 
following manufacturer’s instructions. The solution of XTT labeling and electron 




Net absorbance was then measured (A450-A650) for each sample. Cells grown on 
tissue culture polystyrene were used to set 100% metabolic activity.  
To assess the bioactivity of the incorporated HPM, PEG hydrogels were formed with 
and without HPM. Human umbilical vein endothelial cells (HUVECs) were seeded 
on top of hydrogel scaffolds, and cultured at 37 °C for 3 days. After 3 days, cells 
were lifted using trypsin, and the supernatant was collected and combined with an 
acetic acid rinse of the scaffold. Collagen was quantified using the hydroxyproline 
assay. Hydrogel scaffolds without HUVECs were included as a baseline for collagen 
content within the scaffold.  
6.2.6 Isolation of Bone Marrow 
Whole, unprocessed bone marrow was obtained from male adult Sprague Dawley rats 
and processed as described in published protocols (187, 188). Briefly, bone marrow is 
flushed from the femur and tibia to obtain bone marrow progenitor cells. Cells were 
plated onto non-treated petri dishes in macrophage complete media (DMEM/F12 
supplemented with 10mM glutamine, 100 U/mL penicillin and 100ug/mL 
streptomycin and 10% (v/v) of fetal bovine serum plus 100 U/mL of recombinant 
granulocyte macrophage colony stimulating factor (Peprotech)). At day 4, media was 
supplemented with the same volume of fresh macrophage complete media. After 7 
days of culture, non-adherent cells are eliminated. Adherent cells are harvested with 








6.2.7 Macrophage response to HPM components 
Sterile filtered HPM was added to macrophage culture in the concentrations of 3 
mg/mL, 1.5 mg/mL, and 0.3 mg/mL. As controls, separate macrophages were 
polarized using either 150 U/mL IFNγ or 120 ng/mL IL 4 and 40 ng/mL IL 13 (189). 
After 6 hours, 100 ng/mL lipopolysaccharide was added to control cultures to 
stimulate cells (190). After 6 hours of either HPM or LPS addition, cells were 
harvested using cell scraping to extract RNA. After 24 hours, other groups were fixed 
with 4% paraformaldehyde to stain for cell surface markers and media was collected 
for cytokine analysis. 
6.2.8 Quantitative reverse transcriptase-polymerase chain reaction (QT-PCR) 
RNA was isolated using an RNeasy Mini Plus Kit (Qiagen, Valencia, CA) following 
standard procedures. Isolated RNA was then reverse transcribed to cDNA using a 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
Glyceraldehyde-3-phosphatase dehydrogenase (GAPDH) was used as an endogenous 
control gene for all samples.  
 
Gene expression assays were combined with the cDNA from each sample and 
TaqMan PCR Master Mix II (Applied Biosystems). The reaction was conducted on a 
7900HT real-time PCR system (Applied Biosystems) using thermal conditions of 2 
min at 50 °C, 10 min at 95, and 40 cycles of 15 seconds at 95 and 1 min at 60. The 
relative gene expression level of each target was normalized to the mean of the 
GAPDH level, and then fold change was calculated using the ΔΔCT method. Samples 




6.2.9 Co-culture experiment to evaluate response to ECM Hydrogel 
Rat aortic endothelial cells (RAECs) were purchased from Cell Biologics, and 
cultured according to suppliers instructions. PEG + HPM scaffolds were prepared as 
previously described, following the concentrations in Table 2. To investigate the 
contribution from complete ECM, a PEG + Collagen scaffold was added. RAECs 




) onto hydrogels and cultured at 37 °C for 3 days to 
allow them to come to confluency on the surface of the gel. Naïve monocytes were 




). Media was 
replaced with a mixture of RAEC media and macrophage complete media in a 50:50 
ratio for all samples. For QT-PCR analysis, cells were harvested (n=3 from each 
group) 6 hours after addition of monocytes. Media extracts from the remaining 
scaffolds (n=3 from each group) were taken at 24 hours for cytokine analysis, and the 
scaffolds were fixed using 4% paraformaldehyde 1% sucrose for immunostaining. 
Scaffolds were then rinsed with PBS, followed by a permeabilization buffer and 
background blocker for 15 min. Cells were stained using the following antibody set 
and stains: a mouse anti-CD68 antibody (Abcam, 1:100) and goat anti-mouse FITC 
conjugated secondary antibody (Abcam, 1:200), a rabbit anti-CD206 antibody 
(Abcam,1:600) and a donkey anti-rabbit Alexa Fluor®647 secondary (Abcam, 
1:200), a goat anti-CD86 antibody (Novus Biologics, 1:200) and donkey anti-goat 
Alexa Fluor®555 secondary (Abcam, 1:200), a rabbit anti-von Willebrand Factor 
antibody (Abcam, 1:100) and a donkey anti-rabbit Alexa Fluor®647 secondary 
(1:200), or finally, an actin stain Alexa Fluor® 594 Phalloidin (Invitrogen, 2.5%), and 





Table 6.3 Hydrogel Scaffolds for Co-Culture  
 RBMs RAECs RBMs + RAECs 
1%HPM 6 6 6 
5% PEG 6 6 6 
5%PEG + 0.5% HPM 6 6 6 
5% PEG + 0.1% HPM 6 6 6 
5% PEG + 0.1% Collagen 6 6 6 
 
6.2.10 Statistical Analysis  
Data was analyzed using a one way analysis of variance (ANOVA), followed by a 
post hoc Tukey’s test using a 95% confidence interval. Data plotted represents the 





6.3 Results and Discussion  
The first objective of this study was to extract active matrix components from 
pericardium that could be incorporated into a shape-controlled hydrogel scaffold. 
Bovine pericardium was successfully decellularized and homogenized, resulting in a 
water soluble, protein powder. If reconstituted at 10 mg/mL, the HPM assembles at 
37 °C into a solid hydrogel (as compared to the same formulation at 4°C in Figure 
6.1D, and in a cylindrical mold, Figure 6.1E). From 1 mg of tissue, the final 
components of homogenized pericardium matrix (HPM) were determined to be 0.8 
mg of protein using a Bradford assay. Of that protein, at least 80% was determined to 
be collagen using a hydroxyproline quantification and compared to a collagen control. 
We additionally determined 7.8 μg GAG/mg HPM. Finally, in 10 mg of tissue, less 
than 50 ng of DNA content was detected. These results are detailed in Figure 6.1A. 
To more specifically identify the protein components, samples of HPM were analyzed 
using SDS-PAGE (Figure 6.1B). As shown, the total protein bands in HPM are in 
similar locations to the control rat tail collagen I, but are also present at several other 
distinct locations. Some of these bands where further assessed using antibody specific 






Figure 6. 1 HPM Characterization. Protein quantification and colorimetric assays were used to 
determine the molecular concentrations in the HPM, and displayed as concentrations per mg of dry 
HPM (n=15) (A). HPM was analyzed using SDS-PAGE (B) and stained for total protein. HPM is 
compared to a standard of rat tail collagen I, and arrows indicate bands appearing in HPM that were 
further characterized using antibody specific staining on the right. The final characterization was 
completed using mass spectrometry, and proteins existing in significant quantities are displayed by 
total percent (C). The final product HPM is capable of forming a thermally crosslinked hydrogel, as 
compared to the same material stored at 4C (D). The hydrogel can maintain shape integrity, as shown 






As a control, a sample of gelatin was compared to the HPM electrophoresis (data not 
shown) to ensure the integrity of the protein molecules in HPM. The variety of 
structural proteins were confirmed using mass spectrometry (Figure 6.1C). We were 
able to confirm collagen I, III, VIII and fibrillin. These results support the design of 
using site specific ECM-based source for the bioactivity within a scaffold. Building a 
scaffold using a simple cocktail of collagen I and fibrillin for example, could over 
simplify and eliminate some critical matrix components that HPM provides, such as 
fibronectin for cell adhesion points or GAGs for sequestering growth factors (118). 
The composition of the vascular environment is complex, and distinct from protein 
profiles identified in other tissues.  
 
As described, although HPM is capable of forming a hydrogel on its own, the 
resulting hydrogel is weak and lacks spatial resolution that could be important in 
developing vascular scaffolds. To improve on the mechanical integrity and spatial 
control, we combine HPM with PEGacrylate using a photoinitiated crosslinking 
system. To confirm this reaction is taking place between the HPM and the 
PEGacrylate, we can compare the concentration of free amines before and after 
crosslinking. Crosslinking HPM with PEGacrylate reduced the primary amine 
concentration significantly when compared to the uncrosslinked materials, indicating 
that the free amines in HPM are now bound to acrylates in PEG (Figure 6.2A). 
Similarly, the FTIR spectra of the crosslinked sample displays a reduced peak around 
the 1600 wavenumber compared to the uncrosslinked HPM, demonstrating a change 




HPM hydrogel is seen to lose significantly more mass in both water and with 
collagenase than PEG (-) gels in collagenase (Figure 6.2C). The average mass loss is 
greater than the 1% HPM incorporated into the gels, suggesting that this result is not 
simply the HPM content leaching out of a crosslinked PEG-PEG hydrogel. Taken 
together, these results indicate that a chemically crosslinked network is formed 
between the PEG molecules and the proteins in the HPM, creating a hybrid, 






Figure 6. 2 HPM PEG Hydrogel Formation. A reduction in the total concentration of amines in the 
HPM PEG hydrogel compared to the uncrosslinked components demonstrates successful formation of 
the network (n=3) (A). In the FTIR spectra (B), a change near the 1600 wavenumber also indicates a 
change to the free amine group after crosslinking (n=6). Mass loss from hydrogels over 3 days with 
and without collagenase indicated the biodegradability of the hybrid hydrogels, as compared to PEG (-
) hydrogels (n=5) (C). Compressive modulus was also evaluated in scaffolds formed with varying 




content, however, changes to modulus are also seen as a result of HPM concentration. Images display 
the 3D printing capability of this hydrogel, showing a 5mm hollow prism with 1 mm wall thickness 
(E), and a curved vascular model, with an inner diameter of 6mm and a wall thickness of 1.5mm (F). 
Significance between groups was determined using an ANOVA, with a post hoc Tukey’s test. Groups 




 Compressive modulus of hydrogels with degrees of HPM and PEG was determined 
to demonstrate that the strength of HPM can be supplemented by addition of PEG 
(shown in Figure 6.2D). The range of achievable modulus for the hybrid hydrogel is 
bound by the modulus of the two single component hydrogels: 10% PEGda (-) at 45 
kPa and 1% HPM at 0.5 kPa. We observe that although the modulus of the hybrid 
hydrogels seems to be primarily controlled by the concentration of PEGda included, 
the amount of HPM can have a significant effect on the end result. As an example, the 
10% PEG sample set is significantly stiffer than 10% PEG + 0.1% HPM, which is 
significantly stiffer than 10%PEG with 0.5% HPM. Gels with 5% PEG are all less 
stiff than any of the 10% PEG gels groups, but also have variations based on 
concentration of HPM incorporated. All of these groups (except 5% PEG + 0.5% 
HPM) are significantly distinct from 10% PEG or 1% HPM (the individual 
constituent hydrogels). Other groups have reported significant differences in 
parameters such as endothelial cell proliferation, ECM production, and cell-cell 
network formation on matrices spanning 0.05 to 10 kPa, with different stiffness 
promoting different behaviors (177, 191). In one study, endothelial cell proliferation 
was reported to increase on scaffolds of 20 kPa over scaffolds of 2 kPa (178). This 
indicates that the inclusion of PEG in the HPM scaffold could improve the formation 
of an endothelial layer by increasing the stiffness of the substrate. A well-formed 
endothelial layer could improve the long term success of a vascular graft, as well as 





By successfully forming a photocrosslinked network of PEG and HPM, we can use 
3D printing to achieve spatial control that unobtainable through casting methods. 
Figure 6.1E and Figure 6.1F demonstrate spatial resolution obtained using digital 
light projection (DLP) printing. Figure 6.1F shows a curved vascular graft with an 
inner diameter of 6mm, and a wall thickness of 1.5 mm, fitting approximately the size 
of an infant aortic arch.  
 
After development of this hybrid hydrogel, the second objective of this work was to 
use the scaffold to show an environment that supports vascular regrowth and a 
moderate inflammatory response. We hypothesized that the addition of HPM would 
increase endothelial cell spreading matrix production, due to binding sites in the 
HPM. Furthermore, we hypothesized that the addition of PEG to HPM scaffolds 
would slow or dilute the presentation of ECM molecules, allowing for a decreased 
inflammatory response compared to HPM alone.  
 
We first investigated cell viability in response to our hydrogels based on 
photoinitiator content, since PEG and HPM are established non cytotoxic materials. 
L929 cells seeded onto hydrogels with various initiator concentrations showed 
affected metabolic activities, compared to L929s on plastic (100% metabolic activity) 
and L929s on plastic fixed with methanol (0% metabolic activity). Results indicate 
that the initiator TEA appears to have the largest impact on cell metabolic activity, 
and was therefore kept at or below 0.5% for the remainder of the studies (Figure 




be in part attributed to ineffective crosslinking of the polymers at the highest 
concentrations of initiator.  
 
We next investigated bioactivity of the incorporated HPM using HUVECs. A 
comparison of extracellular collagen production shows significantly higher 
concentrations after 3 days when HUVECs are seeded on PEG + HPM scaffolds 
compared to PEG (-) scaffolds (Figure 6.3B). This result suggests a favorable and 
familiar environment to vascular specific cells, indicated by the construction of tissue 
specific matrix. To confirm, HUVECs on HPM hydrogels and PEG hydrogels were 
stained for cytoskeletal actin to visualize morphology. HUVECs on HPM appear to 
have spread further, and formed more networks (Figure 6.3C). Additionally, RAECs 
seeded on the hydrogels were stained for von Willebrand factor, and show more cell-
cell networks on the HPM hydrogel than the PEG hydrogel (Figure 6.3D).  
 
Similarly, HPM added to macrophage culture directs different polarization depending 
on the concentration of HPM (Figure 6.3E). Looking at the expression of mRNA for 
5 key cytokines, the control populations differ for several genes. In particular, the M2 
control population has a more upregulated CD163 and IL 10 (M2 markers) and 
slightly less upregulated IL 1β and TNFα than the M1 controls. Averaging the fold 
change for all the M1 markers and dividing by the average fold change for the M2 
makers shows a ratio of either more than 1 in the M1 controls, indicating an M1 
phenotype, and less than 1 in the M2 controls, indicating a M2 phenotype (Figure 




similar way to the M2 control, upregulating IL 10 more than the M1 controls. 
However, even though CD 163 is downregulated in this set, the ratio still favors an 
M2 response. As HPM concentration is increased, the IL10 and CD163 expression 
decreases, while IL1β and TNFα slightly increase. These observations are noted in 







Figure 6. 3 Cell Response to Hybrid Hydrogel Components. L929 cells were found to maintain a 
metabolic activity of 70% or greater when TEA concentration was reduced to 0.5% or below  (n=3 cell 




than on PEG (-) hydrogels  (n=3) (B). HUVECs on HPM hydrogels are stained for actin (red) in Figure 
6.3C, and show morphology changes compared to HUVECs on PEG(-). Similarly, RAECs on HPM 
gels show more staining for von Willebrand factor (purple) than RAECs on PEG or PEG +Collagen 
scaffolds (D). RMCs expression of inflammatory or healing genes shows differences in response to 
HPM concentration (E). M1 and M2 control populations are shown after stimulation and polarization 
with soluble cytokines (represented as technical triplicates of RNA from 3 cell cultures). The gene 
profiles are summarized in Figure 6.3 F, showing a ratio of the expression of M1 genes over M2 genes 
for each group. Significance between groups was determined using an ANOVA, with a post hoc 






Using this information, to develop the scaffolds for the co-culture, we combined a 
moderate (0.1%) and large (0.5%) amount of HPM with PEG. RAECs and RMCs 
were grown separately and together on hydrogels of PEG + HPM, PEG (-), HPM (-) 
and PEG + Collagen. PEG and HPM hybrid hydrogels all result in macrophage 
polarizations characterized by upregulated IL 4 and down regulated TNFα compared 
to macrophages on the single component and control scaffolds (Figure 6.4A). 
However, upregulated IL 1β and downregulated CD163 in these same groups results 
in a phenotypic ratio near one (Figure 6.4B). The M1:M2 ratio flips however, when 
RMCs are cultured together with RAECs. This could be a result of matrix or other 
signals produced by the RAECs in response to the different hydrogel scaffolds.  
 
Interestingly, IL10 upregulation increases as more HPM is added to the scaffold. The 
highest expression of this cytokine is observed on 1% HPM scaffolds. IL10 is anti-
inflammatory cytokine, and a known activator and product of the regulatory 
macrophage. These macrophages act to limit tissue damage by reducing the activation 
of M1 macrophages, although they do not appear to participate actively in wound 





Figure 6. 4 Co-Culture of RAECs and RMCs on Hybrid Hydrogels. RMCs expression of 
inflammatory or healing genes shows differences in response to HPM concentration including in the 
hybrid hydrogel (A). The gene profiles are summarized in Figure 6.4B, showing a ratio of the 




expression as a result of the presence of RAECs. Cells in the co-culture on hybrid hydrogels were 
stained for macrophage phenotypic markers CD68 (green, all), CD86 (red, M1), and CD206 (purple, 




The M1:M2 ratio (Figure 6.4B) shows a mixed population of macrophages, with most 
ratios resulting near one. This result is confirmed using immunostaining (Figure 
6.4C) to determine macrophage phenotype through surface markers. Cells positive for 
both markers appear on HPM + PEG scaffolds, regardless of HPM % added. It is 
important to note here that the presence of M1 macrophages, indicating an 
inflammatory response, is not purely pathogenic in vascular tissue regeneration (193). 
In fact, M1 macrophages have been reported to secrete VEGF (117), making them 
relevant in angiogenesis, and M2 macrophages more important for vessel maturation 
(116). In this way, macrophages along a spectrum of phenotypes participate in 
important ways at different times of wound healing. Therefore, the inclusion of HPM 
in the PEG hydrogels could support a moderate response from M1 macrophages, and 
allow for an easy re-polarization to M2 macrophages as healing progresses and more 
HPM is exposed. 
 
We describe here a hydrogel scaffold with bioactivity to support a moderate 
inflammatory response and support endothelial cell growth. Incorporating this 
bioactivity into a gel with spatial and mechanical tenability is especially key 
parameters in vascular tissue. By using a visible light crosslinking system and a DLP 
printer, we have developed a cyto-compatible printing method with excellent 
resolution as an alternative to other extrusion based approaches with the restraint of 
fiber resolution. Additionally the use of visible light and elimination of harmful shear 
stress allow for the encapsulation of cells into the hydrogel during the printing 




Chapter 7: Summary and Future Directions  
7.1 Summary  
In this dissertation, we demonstrate the potential of a biohybrid material for 
cardiovascular tissue engineering, combining synthetic polymers with pericardium 
tissue. This work details the development of two distinct materials that can both 
contribute to endothelial cell growth as well modulate the inflammatory action from 
macrophages by controlled presentation of extracellular matrix (ECM) molecules. 
These two parameters are key indicators of successful tissue development in vascular 
grafts, and suggest strong potential for a permanent living tissue replacement of 
implanted material. A grafting solution that supports functional vessel development in 
the injured site has immense impacts for cardiovascular surgery, especially in young 
patients with congenital cardiovascular disease. Grafting material that supports the re-
growth of a pediatric patient’s own tissue can eliminate multiple operations and 
morbidities associated with congenital heart defects (CHD) and other vascular 
diseases. 
 
The first objective of this work was to develop an ECM-based material for vascular 
wall repair that retains strength during remodeling and promotes functional tissue 
regrowth. Chapter 2 details the development of a novel hybrid material consisting of a 
layer of pericardium tissue and a layer of the biodegradable polymer, poly(propylene 
fumarate) (PPF). This technique was hypothesized to slow the enzymatic degradation 
of the tissue, but avoid chemical crosslinking and masking of molecules beneficial to 




pericardium, which is subject to easy and rapid enzymatic degradation, and GA 
crosslinked pericardium, the chemically crosslinked surgical standard material. A 12-
day in vitro degradation challenge resulted in no significant difference between the 
elastic modulus or 1% yield strength of PPF reinforced pericardium compared to the 
glutaraldehyde (GA) treated pericardium (p<0.05). However, PPF reinforced 
pericardium accumulated significantly less calcification than GA treated pericardium 
in an in vivo subdermal implant. Furthermore, the overall percentage of macrophages 
in responding cells at 6 weeks in vivo is significantly less in PPF reinforced 
pericardium than in GA crosslinked or untreated pericardium. Less overall 
macrophages may explain the observed differences in pericardium degradation and 
remodeling between the PPF reinforced tissue and untreated tissue. These outcomes 
together indicate that PPF reinforcement directs a response that is closer to functional 
healing than the chronic inflammation or foreign body response that could result from 
GA crosslinked or untreated tissue.  
 
The difference in inflammation around the PPF reinforced pericardium compared to 
the untreated pericardium could have impactful outcomes for the use of xenographic 
ECM-based scaffolds in tissue engineering. In chapter 3, we look further into the 
phenotype of macrophages responding to the implants to characterize the relationship 
between inflammation and amount of ECM exposed. After 6 weeks in vivo, the 
untreated pericardium (100% exposed) has more overall staining of macrophages of 
both phenotypes. The GA treated pericardium (0% exposed) has notably more M1 




noted differences in inflammation at the scaffolds motivated the evaluation of PPF in 
isolated cell culture. To determine what contribution, if any, PPF makes to the 
inflammation, it was cultured together with splenocytes and endothelial cells. 
Splenocytes became activated in the presence of PPF films, but not more so than the 
inflammatory control lipopolysaccharide (LPS), and without any strong presence 
from one phenotype over the other. Additionally, PPF was found to induce moderate 
upregulation of tumor necrosis factor α (TNFα) in human endothelial cells 
(HUVECs), but the effect could fade after initial degradation of the PPF within 5 
days. The investigation culminated with a final subdermal implant study in athymic 
rats, to isolate the role of macrophages alone from other immune cells in response to 
3 degrees of pericardium presentation. Fewer overall cells were observed near the 
implants in athymic rats compared to Sprague Dawley (SD) samples, indicating the 
response is markedly different without a full cast of immune system cells. Never the 
less, some differences in macrophage phenotypes were observed. The cells present in 
the high PPF coverage sample had the least intensity of the CD68 general 
macrophage stain. There also appeared to be distinct CD206 stain in both of the PPF 
reinforced samples. This observation after 6 weeks, together with the reduced TNFα 
compared to untreated samples, could indicate a shift in macrophage action towards 
healing and away from inflammation propagation.  
 
Based on results presented in these two chapters, we believe that PPF reinforcement 
is a valuable tool to control the presentation of ECM molecules and could reduce the 




accumulation of matrix breakdown products, cryptic peptides, and M1 macrophages. 
In chapter 4, we describe an approach to utilize this tool as a platform to directionally 
release pro-angiogenic factors to the tissue substrate. This directional and time 
controlled delivery could be used to direct or further promote vascular regrowth and 
reduced inflammation. Specifically, we hypothesized that by using PPF as a scaffold 
to encapsulate poly (lactic-co-glycolic) acid (PLGA) microparticles, a tunable and 
directional release would be achieved from the intact scaffold into the bioactive 
substrate, pericardium. Release of bioactive molecules occurs as PLGA 
microparticles degrade hydrolytically into biocompatible molecules, leaving the PPF 
scaffold unchanged within the release time frame and able to mechanically support 
the pericardium substrate through remodeling. In this proof-of-concept study, we first 
evaluated the degradation time frame and strength of the composite polymer layer. 
We determined the release of encapsulated factors to occur over eight days, while the 
bulk polymer remained intact with near 100% of its original mass. Next, this study 
demonstrated sustained bioactive molecule release from the composite into cell 
culture, causing significant changes to cellular metabolic activity. In particular, 
delivering vascular endothelial growth factor (VEGF) from the composite material to 
endothelial cells increased metabolic activity over the same cells with unloaded 
composite material. Additionally, delivering TNFα from the composite material to 
L929 cells significantly reduced metabolic activity compared to the same cells with 
unloaded composite material (p<0.05). Finally, directional release into a bioactive 
substrate was confirmed with localized immunostaining of encapsulated ovalbumin as 




controlled cytokines and growth factors in the pericardium substrate during 
remodeling as a tool to further promote endothelialization and reduce inflammation.  
 
The material developed as part of this first objective fills the need for a compliant and 
versatile material for use in vascular patches, with demonstrated ability to encourage 
and support functional tissue remodeling. Based on the success of pericardium, the 
second of objective of this work seeks to expand on the potential uses for this 
platform. In chapter 5, we establish through 3D printing a shape and modulus 
controlled hydrogel combining homogenized pericardium and polyethylene glycol 
(PEG). The hybrid hydrogel can retain the benefits discovered in objective one in 
promoting wound healing response and endothelial cell growth in vascular tissue. 
Homogenization of the pericardium tissue resulted in a water soluble powder 
containing a unique profile of collagen, fibrillin, fibronectin, and 
glycosaminoglycans. Through a visible light photoinitiated reaction, the homogenized 
pericardium (HPM) was combined with PEGacrylate, and formed a hydrogel with 
varying modulus depending on concentration of each component between 0.5 and 20 
kPa. Cell viability and preferential growth when compared to PEGacrylate hydrogels 
was evaluated using L929 cells, HUVECs, and ultimately a co-culture of rat aortic 
endothelial cells (RAECs) and rat macrophages (RMCs). HUVECs cultured on HPM 
hydrogels laid more matrix, and maintained a more natural morphology with positive 
von Willebrand factor staining. Macrophages developed an M2 phenotype in 
response to low amounts (0.03%, w/v) of HPM in culture, but responded with 




analysis, both M1 and M2 macrophages were detected, along with a combination of 
both inflammatory and healing cytokines. This result, as discussed in Chapter 5, may 
not be pathogenic, as some inflammation is important to early wound repair. Based 
on results of pericardium in vivo in chapters 2 and 3, as well as pericardium in 
isolated macrophage culture, we suspect this material will support a dynamic shift in 
macrophage population to an M2 dominated environment at later time points. Finally, 
specific shape formation of the biohybrid hydrogel using DLP 3D printing 
demonstrates the utility of this approach to building specific structures for use in 
pediatric congenital heart defect reconstruction.  
 
In conclusion, through this work we have demonstrated the use of an ECM-based 
hybrid material to positively influence cells to respond with healing and repair to a 
vascular graft. A successful tissue engineered vascular graft embodies potential for 
growth, long term incorporation and maintenance in the body. These characteristics 
are essential in the pediatric population, as well as for general cardiovascular disease 
patients. As such, tissue engineered vascular grafts, since they can meet these criteria, 
are a popular area of research. There are several promising approaches currently 
under investigation in animal and even clinical trials. In one such study, a completely 
synthetic but biodegradable polymer scaffold was implanted in sheep. Researchers 
found that the polymer graft was slowly replaced with native cells, which laid new 
collagen and elastic matrix over the graft as it degraded (194). The benefits of this 
purely synthetic approach include a simplified manufacturing method, since a more 




However, it is possible that without control over the cellular infiltration, either 
through biological signals or pre-seeding of cells, over stimulation of the 
inappropriate type of cells could be propagated to quickly lay matrix, ultimately 
leading to inappropriate tissue formation. This possibility is supported by the success 
seen in two different but impactful clinical trials, implementing a blend of polymer 
and cell populations. In one approach, biomimetic in vitro mechanical stimulation is 
used to develop a mechanically functioning graft tissue in vitro. These grafts can be 
developed with non-species specific cells, decellularized, and the reseeded with 
autologous cells (195). It is more than possible that the long term success and 
functional tissue development of these grafts could be related to the biological 
activity of the substrate. In another approach currently in clinical trials, a synthetic 
backbone of degradable polymers is pre-seeded mononuculear cells. The presence of 
these cells is suspected to influence the healing response, and encourage the 
formation of neotissue (193). However, it is interesting to note that the seeded cells 
may not be incorporated into the newly formed tissue, but rather recruit and signal for 
healing and infiltration of nearby cells (196). These graphs demonstrate growth and 
show appropriate vessel tissue formation, although  thickening at anastomosis sites, 
stenosis and thrombosis are still notable concerns for failure at 5.6 years (197). Upon 
further investigation into this mechanism, the stenosis could be macrophage derived 
(193). Control over macrophage infiltration is therefore critical for neovessel 
formation and the inhibition of stenosis. ECM has been described here and in other 




Based on these current investigations, it is clear that a biologically relevant surface 
and scaffold are essential to re-building native tissue around an implant site. The 
material described here builds on the success seen in other grafts with biologically 
relevant surfaces, but incorporates this surface with minimal in vitro cell development 
or without the need for autologous cells. Furthermore, the combination of materials in 
the ratios described here could influence infiltration and matrix breakdown rates, 
which can positively modulate the immune response, and possible reduce 
macrophage directed stenosis. Controlled macrophage population and infiltration, 
appropriate tissue formation, and patency beyond 5 years would be important 
benchmarks to evaluate in the continued development of the hybrid materials 
developed in this thesis. 
 
The ECM-based hybrid material can be enhanced through variations to the 
concentration of polymer, or more overtly by adding bioactive factor reservoirs to the 
polymer layer that can further promote and signal for reconstruction and regrowth. 
Based on these accomplishments, we believe pericardium based biohybrid materials 
are extremely well suited for a tissue engineering strategy for vascular repair. 
Complex pediatric and general cardiac surgeries demand the use of tissue or synthetic 
patch material in reconstruction and repair. As described, outcomes of these surgeries 
would be significantly improved and frequency of subsequent surgeries would be 
decreased with innovative design of material that can create a lasting solution through 





The work presented in this dissertation has resulted in three first author publications, 
along with two manuscripts in the preparation and submission process. My research 
related to this work is included in 3 additional publications. Over the course of my 
research, I was in part supported by the American Heart Association Predoctoral 
Fellowship (# 14PRE20380374) and the National Institute of Health Ruth L. 
Kirschstein National Research Service Award F31 Predoctoral Fellowship (Award 
Number F31HL132541).The novel combination of PPF and pericardium is also 
contained in a full patent application. The work to develop ECM-based biomaterials 
with polymer reinforcement a significant step in tissue to provide a mechanically 
suitable and biologically preferable substrate, with the possibility for long term 
incorporation and remodeling. 
7.3 Future Directions   
The work focused on material development for surgical applications, and provides 
compelling evidence that indicates success as a vascular graft. Future developments 
could begin to prepare this material for interaction with blood in circulation. This 
work could begin with more isolated studies to investigate parameters such as 
compliance and burst pressure in closed system, suture retention or 
hemocompatibility with platelets and coagulation factors. Eventually, studies could 
progress to investigate tissue development in a site specific study in the vascular wall. 
Based on the work presented here, a pro-healing immune and rebuilding response 
would be observed at later time points. Scaffolds would show evidence of new 




fibroblasts, M1 macrophages, and concentrations of inflammatory cytokines. To 
correlate results directly with previous studies, this study could be conducted in SD 
rats in order to observe the healing response to a significant vessel injury with the 
multiple systems at play in vivo. Blood sampled at early time points would help detail 
immune system activated cells. The implanted and surrounding tissue could be 
excised to determine local immune activity and remodeling of the injured site at later 
time points, providing a broad view of the response. 
 
ECM-based implants are currently a field with great attention in tissue engineering. 
The involvement of these molecules in the immune system as whole is a complex 
study, and one that is just beginning to be understood. The results presented in this 
work suggest that pericardium based scaffolds may recruit M1 and initiate other 
inflammatory pathways initially or if exposed in high concentration, but overtime this 
response could shift towards a healing, M2 dominated outcome. An in depth 
investigation into this mechanism could first break down the pericardium into 
categories, including but not limited to: intact proteins, peptide fragments, peptides 
chemically bound to a PEG molecule, etc., and investigate the role that these 
molecules have in overall inflammation. Each of these molecules listed could have 
separate roles, and all may be present at one time or another in the degradation of the 
scaffold (115). A second investigation could test specific components of the 
pericardium compared to other tissue ECMs. Comparisons between other tissues have 
shown different immune activation profiles in recently published work (159, 162). 




immune system would allow the engineer to make more informed and directed design 
changes, specifically regarding synthetic polymer concentration and delivery of 
angiogenic or anti-inflammatory signals.  
 
Finally, the work presented here is aimed at repair for existing and functional 
vasculature. However, many of the same cells and pathways are involved in the 
development of microvasculature into tissue engineered organs or into ischemic zones 
affected by peripheral artery disease. Many of the concepts developed in the hybrid 
hydrogel study could be translatable to promote new vessel development and 
stabilization. To apply this concept, mechanical properties, degradation rates, and 
possible cell encapsulation would be appropriate to areas of optimization for this new 
system. The incorporation of vascular-specific ECM could cause more endothelial 
cells to participate in vascular structure formation by providing signals for 
chemotaxis, proliferation and vascular sprouting. This could be measured by the 
upregulation of angiogenic genes including: VEGF, brain-derived neurotrophic 
factor, platelet derived growth factor, and epidermal growth factor in an in vitro 
study.  
 
The research presented in this thesis, along with future investigations, describes an 
approach to hybrid scaffold development that has potential to dramatically improve 
results for tissue engineered vascular scaffolds. Through the combined incorporation 




polymer, a scaffold can be built that supports ordered remodeling and functional 
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